{"EPHX1": {"11692079": {"pubYear": "2001", "dateOfCreation": "2001-11-05", "pubModel": "Print", "chemicalList": {"chemical": [{"registryNumber": "EC 3.3.2.3", "name": "Epoxide Hydrolases"}]}, "authorString": "Farin FM, Janssen P, Quigley S, Abbott D, Hassett C, Smith-Weller T, Franklin GM, Swanson PD, Longstreth WT, Omiecinski CJ, Checkoway H.", "affiliation": "Department of Environmental Health, University of Washington, Seattle, Washington 98195-7234, USA.", "pubTypeList": {"pubType": ["Journal Article", "Research Support, U.S. Gov't, P.H.S.", "Comparative Study"]}, "grantsList": {"grant": [{"acronym": "ES", "orderIn": 0, "agency": "NIEHS NIH HHS", "grantId": "ES-04696"}, {"acronym": "ES", "orderIn": 0, "agency": "NIEHS NIH HHS", "grantId": "ES10750"}, {"acronym": "ES", "orderIn": 0, "agency": "NIEHS NIH HHS", "grantId": "ES04978"}, {"acronym": "ES", "orderIn": 0, "agency": "NIEHS NIH HHS", "grantId": "ES-07033"}]}, "hasPDF": "N", "id": "11692079", "inEPMC": "N", "authorList": {"author": [{"lastName": "Farin", "fullName": "Farin FM", "initials": "FM"}, {"lastName": "Janssen", "fullName": "Janssen P", "initials": "P"}, {"lastName": "Quigley", "fullName": "Quigley S", "initials": "S"}, {"lastName": "Abbott", "fullName": "Abbott D", "initials": "D"}, {"lastName": "Hassett", "fullName": "Hassett C", "initials": "C"}, {"lastName": "Smith-Weller", "fullName": "Smith-Weller T", "initials": "T"}, {"lastName": "Franklin", "fullName": "Franklin GM", "initials": "GM"}, {"lastName": "Swanson", "fullName": "Swanson PD", "initials": "PD"}, {"lastName": "Longstreth", "fullName": "Longstreth WT Jr", "initials": "WT"}, {"lastName": "Omiecinski", "fullName": "Omiecinski CJ", "initials": "CJ"}, {"lastName": "Checkoway", "fullName": "Checkoway H", "initials": "H"}]}, "title": "Genetic polymorphisms of microsomal and soluble epoxide hydrolase and the risk of Parkinson's disease.", "citedByCount": 6, "source": "MED", "pmid": "11692079", "hasLabsLinks": "Y", "subsetList": {"subset": [{"code": "IM", "name": "Index Medicus"}]}, "meshHeadingList": {"meshHeading": [{"descriptorName": "Cytoplasm", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "EN", "qualifierName": "enzymology", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Microsomes", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "EN", "qualifierName": "enzymology", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Humans", "majorTopic_YN": "N"}, {"descriptorName": "Parkinson Disease", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Epoxide Hydrolases", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Risk Factors", "majorTopic_YN": "N"}, {"descriptorName": "Genotype", "majorTopic_YN": "N"}, {"descriptorName": "Polymorphism, Genetic", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Solubility", "majorTopic_YN": "N"}, {"descriptorName": "Adult", "majorTopic_YN": "N"}, {"descriptorName": "Aged", "majorTopic_YN": "N"}, {"descriptorName": "Aged, 80 and over", "majorTopic_YN": "N"}, {"descriptorName": "Middle Aged", "majorTopic_YN": "N"}, {"descriptorName": "Female", "majorTopic_YN": "N"}, {"descriptorName": "Male", "majorTopic_YN": "N"}]}, "inPMC": "N", "dbCrossReferenceList": {"dbName": ["UNIPROT"]}, "hasTMAccessionNumbers": "N", "hasReferences": "Y", "firstPublicationDate": "2001-11-01", "doi": "10.1097/00008571-200111000-00009", "isOpenAccess": "N", "pageInfo": "703-708", "hasDbCrossReferences": "Y", "abstractText": "Oxidative stress is hypothesized to play a major role in the destruction of dopaminergic neurons, which is associated with Parkinson's disease. Epoxides are potentially reactive intermediates formed through the oxidative metabolism of both exogenous and endogenous substances that contribute to cytotoxic damage mediated by oxidative stress. The microsomal (EPHX1) and soluble (EPHX2) epoxide hydrolases function to regulate the oxidation status of a wide range of xenobiotic- and lipid-derived substrates; therefore, interindividual variation in these pathways may mitigate epoxide-related cellular injury. In this investigation, we examined the potential association between the risk of Parkinson's disease and genetic variation within the EPHX1 and EPHX2 genes. Fluorescent 5' nuclease-based assays were developed to identify the allelic status of individuals with respect to specific single nucleotide polymorphisms in exons 3 and 4 of the EPHX1 gene and exons 8 and 13 of the EPHX2 gene. EPHX1 and EPHX2 genotype data were obtained from 133 idiopathic Parkinson's disease patients and 212 control subjects matched on age, gender and ethnicity. No statistically significant differences were found in the distribution of the reference and variant alleles between Parkinson's disease and control subjects, or when results were stratified by gender. Therefore, common polymorphisms within EPHX1 and EPHX2 do not appear to be important risk factors for Parkinson's disease.", "language": "eng", "dateOfCompletion": "2002-01-28", "fullTextUrlList": {"fullTextUrl": [{"url": "http://dx.doi.org/10.1097/00008571-200111000-00009", "documentStyle": "doi", "availability": "Subscription required", "availabilityCode": "S", "site": "LWWonline"}]}, "hasTextMinedTerms": "N", "dateOfRevision": "2007-11-14", "hasBook": "N", "journalInfo": {"printPublicationDate": "2001-11-01", "journal": {"title": "Pharmacogenetics", "issn": "0960-314X", "isoabbreviation": "Pharmacogenetics", "medlineAbbreviation": "Pharmacogenetics", "nlmid": "9211735"}, "monthOfPublication": 11, "volume": "11", "yearOfPublication": 2001, "journalIssueId": 1026355, "issue": "8", "dateOfPublication": "2001 Nov"}}}, "SOD2": {"11161607": {"pubYear": "2001", "dateOfCreation": "2001-02-22", "pubModel": "Print", "chemicalList": {"chemical": [{"registryNumber": "490-79-9", "name": "2,5-dihydroxybenzoic acid"}, {"registryNumber": "504-88-1", "name": "3-nitropropionic acid"}, {"registryNumber": "141-82-2", "name": "malonic acid"}, {"registryNumber": "51-61-6", "name": "Dopamine"}, {"registryNumber": "0", "name": "Carrier Proteins"}, {"registryNumber": "0", "name": "Propionic Acids"}, {"registryNumber": "0", "name": "Nerve Tissue Proteins"}, {"registryNumber": "0", "name": "Hydroxybenzoic Acids"}, {"registryNumber": "306-08-1", "name": "Homovanillic Acid"}, {"registryNumber": "0", "name": "Nitro Compounds"}, {"registryNumber": "EC 1.15.1.1", "name": "Superoxide Dismutase"}, {"registryNumber": "0", "name": "Malonates"}, {"registryNumber": "0", "name": "Membrane Transport Proteins"}, {"registryNumber": "0", "name": "Neurotoxins"}, {"registryNumber": "102-32-9", "name": "3,4-Dihydroxyphenylacetic Acid"}, {"registryNumber": "0", "name": "Gentisates"}, {"registryNumber": "3352-57-6", "name": "Hydroxyl Radical"}, {"registryNumber": "0", "name": "Membrane Glycoproteins"}, {"registryNumber": "69-72-7", "name": "Salicylic Acid"}, {"registryNumber": "28289-54-5", "name": "1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine"}, {"registryNumber": "0", "name": "Dopamine Plasma Membrane Transport Proteins"}]}, "authorString": "Andreassen OA, Ferrante RJ, Dedeoglu A, Albers DW, Klivenyi P, Carlson EJ, Epstein CJ, Beal MF.", "affiliation": "Neurochemistry Laboratory, Massachusetts General Hospital, Boston, Massachusetts, USA.", "pubTypeList": {"pubType": ["Journal Article", "Research Support, Non-U.S. Gov't", "Research Support, U.S. Gov't, Non-P.H.S.", "Research Support, U.S. Gov't, P.H.S."]}, "grantsList": {"grant": [{"acronym": "AG", "orderIn": 0, "agency": "NIA NIH HHS", "grantId": "AG13846"}, {"acronym": "NS", "orderIn": 0, "agency": "NINDS NIH HHS", "grantId": "NS38180"}, {"acronym": "NS", "orderIn": 0, "agency": "NINDS NIH HHS", "grantId": "NS37102"}, {"acronym": "NS", "orderIn": 0, "agency": "NINDS NIH HHS", "grantId": "NS35255"}]}, "hasPDF": "N", "id": "11161607", "inEPMC": "N", "authorList": {"author": [{"lastName": "Andreassen", "fullName": "Andreassen OA", "authorId": {"type": "ORCID", "value": "0000-0002-4461-3568"}, "initials": "OA"}, {"lastName": "Ferrante", "fullName": "Ferrante RJ", "initials": "RJ"}, {"lastName": "Dedeoglu", "fullName": "Dedeoglu A", "authorId": {"type": "ORCID", "value": "0000-0003-1156-0874"}, "initials": "A"}, {"lastName": "Albers", "fullName": "Albers DW", "initials": "DW"}, {"lastName": "Klivenyi", "fullName": "Klivenyi P", "initials": "P"}, {"lastName": "Carlson", "fullName": "Carlson EJ", "initials": "EJ"}, {"lastName": "Epstein", "fullName": "Epstein CJ", "initials": "CJ"}, {"lastName": "Beal", "fullName": "Beal MF", "initials": "MF"}]}, "title": "Mice with a partial deficiency of manganese superoxide dismutase show increased vulnerability to the mitochondrial toxins malonate, 3-nitropropionic acid, and MPTP.", "citedByCount": 44, "source": "MED", "pmid": "11161607", "hasLabsLinks": "N", "subsetList": {"subset": [{"code": "IM", "name": "Index Medicus"}]}, "authorIdList": {"authorId": [{"type": "ORCID", "value": "0000-0002-4461-3568"}, {"type": "ORCID", "value": "0000-0003-1156-0874"}]}, "meshHeadingList": {"meshHeading": [{"descriptorName": "Corpus Striatum", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Mitochondria", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Animals", "majorTopic_YN": "N"}, {"descriptorName": "Mice, Knockout", "majorTopic_YN": "N"}, {"descriptorName": "Mice", "majorTopic_YN": "N"}, {"descriptorName": "Neurodegenerative Diseases", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "CI", "qualifierName": "chemically induced", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Disease Models, Animal", "majorTopic_YN": "N"}, {"descriptorName": "Genetic Predisposition to Disease", "majorTopic_YN": "Y", "meshQualifierList": {"meshQualifier": [{"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}]}}, {"descriptorName": "Hydroxyl Radical", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Dopamine", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Malonates", "majorTopic_YN": "N"}, {"descriptorName": "Propionic Acids", "majorTopic_YN": "N"}, {"descriptorName": "Hydroxybenzoic Acids", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Salicylic Acid", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Gentisates", "majorTopic_YN": "Y"}, {"descriptorName": "3,4-Dihydroxyphenylacetic Acid", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Homovanillic Acid", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Nitro Compounds", "majorTopic_YN": "N"}, {"descriptorName": "1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine", "majorTopic_YN": "N"}, {"descriptorName": "Superoxide Dismutase", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DF", "qualifierName": "deficiency", "majorTopic_YN": "Y"}, {"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}]}}, {"descriptorName": "Carrier Proteins", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Membrane Transport Proteins", "majorTopic_YN": "Y"}, {"descriptorName": "Membrane Glycoproteins", "majorTopic_YN": "Y"}, {"descriptorName": "Nerve Tissue Proteins", "majorTopic_YN": "Y"}, {"descriptorName": "Neurotoxins", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}, {"abbreviation": "TO", "qualifierName": "toxicity", "majorTopic_YN": "N"}]}}, {"descriptorName": "Heterozygote", "majorTopic_YN": "N"}, {"descriptorName": "Female", "majorTopic_YN": "N"}, {"descriptorName": "Male", "majorTopic_YN": "N"}, {"descriptorName": "Dopamine Plasma Membrane Transport Proteins", "majorTopic_YN": "N"}]}, "inPMC": "N", "dbCrossReferenceList": {"dbName": ["UNIPROT"]}, "hasTMAccessionNumbers": "N", "hasReferences": "Y", "firstPublicationDate": "2001-01-01", "doi": "10.1006/exnr.2000.7525", "isOpenAccess": "N", "pageInfo": "189-195", "hasDbCrossReferences": "Y", "abstractText": "There is substantial evidence implicating mitochondrial dysfunction and free radical generation as major mechanisms of neuronal death in neurodegenerative diseases. The major free radical scavenging enzyme in mitochondria is manganese superoxide dismutase (SOD2). In the present study we investigated the susceptibility of mice with a partial deficiency of SOD2 to the neurotoxins 1-methyl-4-phenyl-1,2,5,6-tetrahydropyridine (MPTP), 3-nitropropionic acid (3-NP), and malonate, which are commonly used animal models of Parkinson's and Huntington's disease. Heterozygous SOD2 knockout (SOD2(+/-)) mice showed no evidence of neuropathological or behavioral abnormalities at 2-4 months of age. Compared to littermate wild-type mice, mice with partial SOD2 deficiency showed increased vulnerability to dopamine depletion after systemic MPTP treatment and significantly larger striatal lesions produced by both 3-NP and malonate. SOD2(+/-) mice also showed an increased production of \"hydroxyl\" radicals after malonate injection measured with the salicylate hydroxyl radical trapping method. These results provide further evidence that reactive oxygen species play an important role in the neurotoxicity of MPTP, malonate, and 3-NP. These findings show that a subclinical deficiency in a free radical scavenging enzyme may act in concert with environmental toxins to produce selective neurodegeneration.", "language": "eng", "dateOfCompletion": "2001-03-08", "fullTextUrlList": {"fullTextUrl": [{"url": "http://dx.doi.org/10.1006/exnr.2000.7525", "documentStyle": "doi", "availability": "Subscription required", "availabilityCode": "S", "site": "ScienceDirect"}]}, "hasTextMinedTerms": "N", "dateOfRevision": "2007-11-14", "hasBook": "N", "journalInfo": {"printPublicationDate": "2001-01-01", "journal": {"medlineAbbreviation": "Exp Neurol", "isoabbreviation": "Exp. Neurol.", "title": "Experimental neurology", "issn": "0014-4886", "nlmid": "0370712", "essn": "1090-2430"}, "monthOfPublication": 1, "volume": "167", "yearOfPublication": 2001, "journalIssueId": 949092, "issue": "1", "dateOfPublication": "2001 Jan"}}, "23727323": {"pubYear": "2013", "dateOfCreation": "2013-07-23", "pubModel": "Print-Electronic", "chemicalList": {"chemical": [{"registryNumber": "EC 1.15.1.1", "name": "Superoxide Dismutase"}, {"registryNumber": "11062-77-4", "name": "Superoxides"}, {"registryNumber": "EC 1.15.1.1", "name": "superoxide dismutase 2"}, {"registryNumber": "BBX060AN9V", "name": "Hydrogen Peroxide"}]}, "authorString": "Flynn JM, Melov S.", "affiliation": "Buck Institute for Research on Aging, Novato, CA 94945, USA.", "pubTypeList": {"pubType": ["Journal Article", "Review", "Research Support, Non-U.S. Gov't", "Research Support, N.I.H., Extramural"]}, "grantsList": {"grant": [{"acronym": "AG", "orderIn": 0, "agency": "NIA NIH HHS", "grantId": "AG18675"}, {"acronym": "AG", "orderIn": 0, "agency": "NIA NIH HHS", "grantId": "P01 AG025901"}, {"acronym": "AG", "orderIn": 0, "agency": "NIA NIH HHS", "grantId": "T32AG000266"}, {"acronym": "AG", "orderIn": 0, "agency": "NIA NIH HHS", "grantId": "P30AG025708"}, {"acronym": "AG", "orderIn": 0, "agency": "NIA NIH HHS", "grantId": "T32 AG000266"}, {"acronym": "AG", "orderIn": 0, "agency": "NIA NIH HHS", "grantId": "P01AG025901"}]}, "hasPDF": "Y", "id": "23727323", "inEPMC": "Y", "authorList": {"author": [{"affiliation": "Buck Institute for Research on Aging, Novato, CA 94945, USA.", "fullName": "Flynn JM", "initials": "JM", "firstName": "James M", "lastName": "Flynn"}, {"lastName": "Melov", "fullName": "Melov S", "firstName": "Simon", "initials": "S"}]}, "title": "SOD2 in mitochondrial dysfunction and neurodegeneration.", "hasSuppl": "N", "citedByCount": 27, "source": "MED", "pmid": "23727323", "hasLabsLinks": "N", "subsetList": {"subset": [{"code": "IM", "name": "Index Medicus"}]}, "meshHeadingList": {"meshHeading": [{"descriptorName": "Brain", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Mitochondria", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "EN", "qualifierName": "enzymology", "majorTopic_YN": "N"}, {"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Humans", "majorTopic_YN": "N"}, {"descriptorName": "Neurodegenerative Diseases", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Mitochondrial Diseases", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Hydrogen Peroxide", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Superoxides", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Superoxide Dismutase", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Oxidation-Reduction", "majorTopic_YN": "Y"}, {"descriptorName": "Oxidative Phosphorylation", "majorTopic_YN": "N"}]}, "inPMC": "Y", "hasTMAccessionNumbers": "N", "hasReferences": "Y", "firstPublicationDate": "2013-05-29", "doi": "10.1016/j.freeradbiomed.2013.05.027", "isOpenAccess": "N", "pageInfo": "4-12", "pmcid": "PMC3811078", "hasDbCrossReferences": "N", "keywordList": {"keyword": ["Mitochondria", "Superoxide dismutase", "Aging", "Oxidative stress", "Free radicals", "Neurodegeneration"]}, "abstractText": "The brain is a highly metabolically active tissue that critically relies on oxidative phosphorylation as a means for maintaining energy. One result of this process is the production of potentially damaging radicals such as the superoxide anion (O2(-)). Superoxide has the capacity to damage components of the electron transport chain and other cellular constituents. Eukaryotic systems have evolved defenses against such damaging moieties, the chief member of which is superoxide dismutase (SOD2), an enzyme that efficiently converts superoxide to the less reactive hydrogen peroxide (H2O2), which can freely diffuse across the mitochondrial membrane. Loss of SOD2 activity can result in numerous pathological phenotypes in metabolically active tissues, particularly within the central nervous system. We review SOD2's potential involvement in the progression of neurodegenerative diseases such as stroke and Alzheimer and Parkinson diseases, as well as its potential role in \"normal\" age-related cognitive decline. We also examine in vivo models of endogenous oxidative damage based upon the loss of SOD2 and associated neurological phenotypes in relation to human neurodegenerative disorders.", "electronicPublicationDate": "2013-05-29", "language": "eng", "dateOfCompletion": "2013-11-01", "fullTextUrlList": {"fullTextUrl": [{"url": "http://europepmc.org/articles/PMC3811078?pdf=render", "documentStyle": "pdf", "availability": "Free", "availabilityCode": "F", "site": "Europe_PMC"}, {"url": "http://europepmc.org/articles/PMC3811078", "documentStyle": "html", "availability": "Free", "availabilityCode": "F", "site": "Europe_PMC"}, {"url": "http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=EBI&pubmedid=23727323&action=stream&blobtype=pdf", "documentStyle": "pdf", "availability": "Free", "availabilityCode": "F", "site": "PubMedCentral"}, {"url": "http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=EBI&pubmedid=23727323", "documentStyle": "html", "availability": "Free", "availabilityCode": "F", "site": "PubMedCentral"}, {"url": "http://dx.doi.org/10.1016/j.freeradbiomed.2013.05.027", "documentStyle": "doi", "availability": "Subscription required", "availabilityCode": "S", "site": "DOI"}]}, "hasTextMinedTerms": "Y", "dateOfRevision": "2014-09-02", "hasBook": "N", "journalInfo": {"printPublicationDate": "2013-09-01", "journal": {"medlineAbbreviation": "Free Radic Biol Med", "isoabbreviation": "Free Radic. Biol. Med.", "title": "Free radical biology & medicine", "issn": "0891-5849", "nlmid": "8709159", "essn": "1873-4596"}, "monthOfPublication": 9, "volume": "62", "yearOfPublication": 2013, "journalIssueId": 2059156, "dateOfPublication": "2013 Sep"}}, "23785434": {"pubYear": "2013", "dateOfCreation": "2013-06-20", "pubModel": "Electronic-Print", "chemicalList": {"chemical": [{"registryNumber": "EC 1.15.1.1", "name": "Superoxide Dismutase"}, {"registryNumber": "EC 1.15.1.1", "name": "superoxide dismutase 2"}]}, "authorString": "de Carvalho MD, De Mesquita JF.", "affiliation": "Bioinformatics and Computational Biology Group, Department of Genetics and Molecular Biology, Federal University of Rio de Janeiro State, Rio de Janeiro, Brazil.", "pubTypeList": {"pubType": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "hasPDF": "Y", "id": "23785434", "inEPMC": "Y", "authorList": {"author": [{"affiliation": "Bioinformatics and Computational Biology Group, Department of Genetics and Molecular Biology, Federal University of Rio de Janeiro State, Rio de Janeiro, Brazil.", "fullName": "de Carvalho MD", "initials": "MD", "firstName": "Mariana Dias Castela", "lastName": "de Carvalho"}, {"lastName": "De Mesquita", "fullName": "De Mesquita JF", "firstName": "Joelma Freire", "initials": "JF"}]}, "title": "Structural modeling and in silico analysis of human superoxide dismutase 2.", "hasSuppl": "N", "citedByCount": 4, "source": "MED", "pmid": "23785434", "hasLabsLinks": "N", "tmAccessionTypeList": {"accessionType": ["pdb", " sprot", " "]}, "subsetList": {"subset": [{"code": "IM", "name": "Index Medicus"}]}, "meshHeadingList": {"meshHeading": [{"descriptorName": "Humans", "majorTopic_YN": "N"}, {"descriptorName": "Superoxide Dismutase", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "CH", "qualifierName": "chemistry", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Sequence Alignment", "majorTopic_YN": "N"}, {"descriptorName": "Computational Biology", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "N"}]}}, {"descriptorName": "Amino Acid Sequence", "majorTopic_YN": "N"}, {"descriptorName": "Conserved Sequence", "majorTopic_YN": "N"}, {"descriptorName": "Protein Conformation", "majorTopic_YN": "N"}, {"descriptorName": "Mutation", "majorTopic_YN": "N"}, {"descriptorName": "Polymorphism, Single Nucleotide", "majorTopic_YN": "N"}, {"descriptorName": "Models, Molecular", "majorTopic_YN": "Y"}, {"descriptorName": "Computer Simulation", "majorTopic_YN": "N"}, {"descriptorName": "Internet", "majorTopic_YN": "N"}, {"descriptorName": "User-Computer Interface", "majorTopic_YN": "N"}, {"descriptorName": "Molecular Sequence Data", "majorTopic_YN": "N"}, {"descriptorName": "Databases, Genetic", "majorTopic_YN": "N"}]}, "inPMC": "Y", "hasTMAccessionNumbers": "Y", "hasReferences": "Y", "firstPublicationDate": "2013-06-13", "doi": "10.1371/journal.pone.0065558", "isOpenAccess": "Y", "pageInfo": "e65558", "pmcid": "PMC3681941", "hasDbCrossReferences": "N", "abstractText": "Aging in the world population has increased every year. Superoxide dismutase 2 (Mn-SOD or SOD2) protects against oxidative stress, a main factor influencing cellular longevity. Polymorphisms in SOD2 have been associated with the development of neurodegenerative diseases, such as Alzheimer's and Parkinson's disease, as well as psychiatric disorders, such as schizophrenia, depression and bipolar disorder. In this study, all of the described natural variants (S10I, A16V, E66V, G76R, I82T and R156W) of SOD2 were subjected to in silico analysis using eight different algorithms: SNPeffect, PolyPhen-2, PhD-SNP, PMUT, SIFT, SNAP, SNPs&GO and nsSNPAnalyzer. This analysis revealed disparate results for a few of the algorithms. The results showed that, from at least one algorithm, each amino acid substitution appears to harmfully affect the protein. Structural theoretical models were created for variants through comparative modelling performed using the MHOLline server (which includes MODELLER and PROCHECK) and ab initio modelling, using the I-Tasser server. The predicted models were evaluated using TM-align, and the results show that the models were constructed with high accuracy. The RMSD values of the modelled mutants indicated likely pathogenicity for all missense mutations. Structural phylogenetic analysis using ConSurf revealed that human SOD2 is highly conserved. As a result, a human-curated database was generated that enables biologists and clinicians to explore SOD2 nsSNPs, including predictions of their effects and visualisation of the alignment of both the wild-type and mutant structures. The database is freely available at http://bioinfogroup.com/database and will be regularly updated.", "electronicPublicationDate": "2013-06-13", "language": "eng", "dateOfCompletion": "2014-01-21", "fullTextUrlList": {"fullTextUrl": [{"url": "http://europepmc.org/articles/PMC3681941?pdf=render", "documentStyle": "pdf", "availability": "Open access", "availabilityCode": "OA", "site": "Europe_PMC"}, {"url": "http://europepmc.org/articles/PMC3681941", "documentStyle": "html", "availability": "Open access", "availabilityCode": "OA", "site": "Europe_PMC"}, {"url": "http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=EBI&pubmedid=23785434&action=stream&blobtype=pdf", "documentStyle": "pdf", "availability": "Free", "availabilityCode": "F", "site": "PubMedCentral"}, {"url": "http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=EBI&pubmedid=23785434", "documentStyle": "html", "availability": "Free", "availabilityCode": "F", "site": "PubMedCentral"}, {"url": "http://dx.doi.org/10.1371/journal.pone.0065558", "documentStyle": "doi", "availability": "Subscription required", "availabilityCode": "S", "site": "DOI"}]}, "hasTextMinedTerms": "Y", "hasBook": "N", "journalInfo": {"printPublicationDate": "2013-01-01", "journal": {"title": "PloS one", "medlineAbbreviation": "PLoS One", "isoabbreviation": "PLoS ONE", "nlmid": "101285081", "essn": "1932-6203"}, "monthOfPublication": 0, "volume": "8", "yearOfPublication": 2013, "journalIssueId": 2046964, "issue": "6", "dateOfPublication": "2013 "}}, "25279756": {"pubYear": "2014", "dateOfCreation": "2014-10-04", "pubModel": "Electronic-eCollection", "chemicalList": {"chemical": [{"registryNumber": "0", "name": "RNA, Messenger"}, {"registryNumber": "EC 1.15.1.1", "name": "Superoxide Dismutase"}, {"registryNumber": "EC 1.15.1.1", "name": "superoxide dismutase 2"}, {"registryNumber": "0", "name": "Biomarkers"}]}, "authorString": "Santiago JA, Scherzer CR, Potashkin JA.", "affiliation": "The Cellular and Molecular Pharmacology Department, The Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, United States of America.", "pubTypeList": {"pubType": ["Journal Article", "Research Support, Non-U.S. Gov't", "Research Support, U.S. Gov't, Non-P.H.S.", "Research Support, N.I.H., Extramural"]}, "grantsList": {"grant": [{"acronym": "NS", "orderIn": 0, "agency": "NINDS NIH HHS", "grantId": "P01 NS058793"}, {"acronym": "AG", "orderIn": 0, "agency": "NIA NIH HHS", "grantId": "P50 AG005134"}, {"acronym": "AG", "orderIn": 0, "agency": "NIA NIH HHS", "grantId": "R01 AG044113"}, {"acronym": "NS", "orderIn": 0, "agency": "NINDS NIH HHS", "grantId": "U01 NS082157"}, {"acronym": "AT", "orderIn": 0, "agency": "NCCIH NIH HHS", "grantId": "U01 AT000613"}, {"acronym": "NS", "orderIn": 0, "agency": "NINDS NIH HHS", "grantId": "U01 NS082080"}, {"acronym": "NS", "orderIn": 0, "agency": "NINDS NIH HHS", "grantId": "R01 NS064155"}]}, "hasPDF": "Y", "id": "25279756", "inEPMC": "Y", "authorList": {"author": [{"affiliation": "The Cellular and Molecular Pharmacology Department, The Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, United States of America.", "fullName": "Santiago JA", "initials": "JA", "firstName": "Jose A", "lastName": "Santiago"}, {"affiliation": "The Neurogenomics Laboratory, Harvard Medical School and Brigham and Women's Hospital, Cambridge, Massachusetts, United States of America.", "fullName": "Scherzer CR", "initials": "CR", "firstName": "Clemens R", "lastName": "Scherzer"}, {"affiliation": "The Cellular and Molecular Pharmacology Department, The Chicago Medical School, Rosalind Franklin University of Medicine and Science, North Chicago, Illinois, United States of America.", "fullName": "Potashkin JA", "initials": "JA", "firstName": "Judith A", "lastName": "Potashkin"}]}, "title": "Network analysis identifies SOD2 mRNA as a potential biomarker for Parkinson's disease.", "hasSuppl": "N", "citedByCount": 8, "source": "MED", "pmid": "25279756", "hasLabsLinks": "Y", "subsetList": {"subset": [{"code": "IM", "name": "Index Medicus"}]}, "meshHeadingList": {"meshHeading": [{"descriptorName": "Humans", "majorTopic_YN": "N"}, {"descriptorName": "Parkinson Disease", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DI", "qualifierName": "diagnosis", "majorTopic_YN": "Y"}, {"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}]}}, {"descriptorName": "Diabetes Mellitus, Type 2", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}]}}, {"descriptorName": "Superoxide Dismutase", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "Y"}]}}, {"descriptorName": "RNA, Messenger", "majorTopic_YN": "Y"}, {"descriptorName": "Up-Regulation", "majorTopic_YN": "Y"}, {"descriptorName": "Algorithms", "majorTopic_YN": "N"}, {"descriptorName": "Databases, Genetic", "majorTopic_YN": "N"}, {"descriptorName": "Aged", "majorTopic_YN": "N"}, {"descriptorName": "Middle Aged", "majorTopic_YN": "N"}, {"descriptorName": "Male", "majorTopic_YN": "N"}, {"descriptorName": "Gene Regulatory Networks", "majorTopic_YN": "N"}, {"descriptorName": "Biomarkers", "majorTopic_YN": "N"}]}, "inPMC": "N", "hasTMAccessionNumbers": "N", "hasReferences": "Y", "firstPublicationDate": "2014-10-03", "language": "eng", "doi": "10.1371/journal.pone.0109042", "isOpenAccess": "Y", "pageInfo": "e109042", "pmcid": "PMC4184821", "hasDbCrossReferences": "N", "abstractText": "Increasing evidence indicates that Parkinson's disease (PD) and type 2 diabetes (T2DM) share dysregulated molecular networks. We identified 84 genes shared between PD and T2DM from curated disease-gene databases. Nitric oxide biosynthesis, lipid and carbohydrate metabolism, insulin secretion and inflammation were identified as common dysregulated pathways. A network prioritization approach was implemented to rank genes according to their distance to seed genes and their involvement in common biological pathways. Quantitative polymerase chain reaction assays revealed that a highly ranked gene, superoxide dismutase 2 (SOD2), is upregulated in PD patients compared to healthy controls in 192 whole blood samples from two independent clinical trials, the Harvard Biomarker Study (HBS) and the Diagnostic and Prognostic Biomarkers in Parkinson's disease (PROBE). The results from this study reinforce the idea that shared molecular networks between PD and T2DM provides an additional source of biologically meaningful biomarkers. Evaluation of this biomarker in de novo PD patients and in a larger prospective longitudinal study is warranted.", "electronicPublicationDate": "2014-10-03", "license": "cc by", "dateOfCompletion": "2015-12-17", "fullTextUrlList": {"fullTextUrl": [{"url": "http://europepmc.org/articles/PMC4184821?pdf=render", "documentStyle": "pdf", "availability": "Open access", "availabilityCode": "OA", "site": "Europe_PMC"}, {"url": "http://europepmc.org/articles/PMC4184821", "documentStyle": "html", "availability": "Open access", "availabilityCode": "OA", "site": "Europe_PMC"}, {"url": "http://dx.doi.org/10.1371/journal.pone.0109042", "documentStyle": "doi", "availability": "Subscription required", "availabilityCode": "S", "site": "DOI"}]}, "hasTextMinedTerms": "Y", "dateOfRevision": "2015-06-15", "hasBook": "N", "journalInfo": {"printPublicationDate": "2014-01-01", "journal": {"title": "PloS one", "medlineAbbreviation": "PLoS One", "isoabbreviation": "PLoS ONE", "nlmid": "101285081", "essn": "1932-6203"}, "monthOfPublication": 0, "volume": "9", "yearOfPublication": 2014, "journalIssueId": 2206285, "issue": "10", "dateOfPublication": "2014 "}}, "10561523": {"pubYear": "1999", "dateOfCreation": "1999-12-23", "pubModel": "Print", "chemicalList": {"chemical": [{"registryNumber": "0", "name": "Levodopa"}, {"registryNumber": "0", "name": "Antiparkinson Agents"}, {"registryNumber": "25614-03-3", "name": "Bromocriptine"}, {"registryNumber": "EC 1.15.1.1", "name": "Superoxide Dismutase"}, {"registryNumber": "3352-57-6", "name": "Hydroxyl Radical"}, {"registryNumber": "66104-22-1", "name": "Pergolide"}]}, "authorString": "Ihara Y, Chuda M, Kuroda S, Hayabara T.", "affiliation": "Clinical Research Institute and Department of Neurology, National Minamiokayama Hospital, 4066 Hayashima-cho, Tsukubo-gun, Okayama, Japan. iharay@sokayama.hosp.go.jp", "pubTypeList": {"pubType": ["Journal Article", "Comparative Study"]}, "hasPDF": "N", "id": "10561523", "inEPMC": "N", "authorList": {"author": [{"lastName": "Ihara", "fullName": "Ihara Y", "initials": "Y"}, {"lastName": "Chuda", "fullName": "Chuda M", "initials": "M"}, {"lastName": "Kuroda", "fullName": "Kuroda S", "initials": "S"}, {"lastName": "Hayabara", "fullName": "Hayabara T", "initials": "T"}]}, "title": "Hydroxyl radical and superoxide dismutase in blood of patients with Parkinson's disease: relationship to clinical data.", "citedByCount": 27, "pageInfo": "90-95", "source": "MED", "pmid": "10561523", "hasLabsLinks": "N", "subsetList": {"subset": [{"code": "IM", "name": "Index Medicus"}]}, "meshHeadingList": {"meshHeading": [{"descriptorName": "Erythrocytes", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "EN", "qualifierName": "enzymology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Humans", "majorTopic_YN": "N"}, {"descriptorName": "Multiple System Atrophy", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "BL", "qualifierName": "blood", "majorTopic_YN": "N"}]}}, {"descriptorName": "Parkinson Disease", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "BL", "qualifierName": "blood", "majorTopic_YN": "Y"}, {"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Disease Progression", "majorTopic_YN": "N"}, {"descriptorName": "Hydroxyl Radical", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "BL", "qualifierName": "blood", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Levodopa", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "N"}]}}, {"descriptorName": "Pergolide", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "N"}]}}, {"descriptorName": "Bromocriptine", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "N"}]}}, {"descriptorName": "Superoxide Dismutase", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "BL", "qualifierName": "blood", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Antiparkinson Agents", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "N"}]}}, {"descriptorName": "Severity of Illness Index", "majorTopic_YN": "N"}, {"descriptorName": "Age Factors", "majorTopic_YN": "N"}, {"descriptorName": "Age of Onset", "majorTopic_YN": "N"}, {"descriptorName": "Time Factors", "majorTopic_YN": "N"}, {"descriptorName": "Aged", "majorTopic_YN": "N"}, {"descriptorName": "Middle Aged", "majorTopic_YN": "N"}, {"descriptorName": "Statistics as Topic", "majorTopic_YN": "N"}]}, "inPMC": "N", "hasTMAccessionNumbers": "N", "hasReferences": "Y", "firstPublicationDate": "1999-11-01", "doi": "10.1016/s0022-510x(99)00192-6", "isOpenAccess": "N", "commentCorrectionList": {"commentCorrection": [{"source": "MED", "orderIn": 1, "type": "Comment in", "id": "10561521", "reference": "J Neurol Sci. 1999 Nov 30;170(2):75-6"}]}, "hasDbCrossReferences": "N", "abstractText": "Hydroxyl radical (.OH) levels in blood, superoxide dismutase (SOD) activity in plasma (plasma-SOD) and in red blood cells (RBC) relative to Cu,Zn-SOD (SOD1) protein (RBC-SOD/SOD1), SOD1 protein in RBC (SOD1/RBC) and plasma (SOD1/plasma), and Mn-SOD protein in plasma (SOD2/plasma) were measured in patients with Parkinson's disease (PD), multiple-system atrophy (MSA) with parkinsonism, and in control subjects. Patients with PD had significantly higher.OH and plasma-SOD values and significantly lower RBC-SOD/SOD1 and SOD1/RBC values than the corresponding MSA and control values. In PD, RBC-SOD/SOD1 values were significantly lower in older patients and were negatively correlated with age.OH levels were significantly higher in PD patients with early onset, a long period of illness or severe Yahr stage, and were negatively correlated with onset and positively correlated with duration of illness. RBC-SOD/SOD1 values in PD patients who received pergolide therapy were significantly higher than those in PD patients who received neither pergolide nor bromocriptine therapy. Therefore, the higher.OH level and the lower SOD1 activity may play a role in the onset and progression of PD, and pergolide may act neuroprotectively by inducing SOD1 activity.", "language": "eng", "dateOfCompletion": "1999-12-23", "fullTextUrlList": {"fullTextUrl": [{"url": "http://dx.doi.org/10.1016/S0022-510X(99)00192-6", "documentStyle": "doi", "availability": "Subscription required", "availabilityCode": "S", "site": "ScienceDirect"}]}, "hasTextMinedTerms": "N", "dateOfRevision": "2007-11-15", "hasBook": "N", "journalInfo": {"printPublicationDate": "1999-11-01", "journal": {"medlineAbbreviation": "J Neurol Sci", "isoabbreviation": "J. Neurol. Sci.", "title": "Journal of the neurological sciences", "issn": "0022-510X", "nlmid": "0375403", "essn": "1878-5883"}, "monthOfPublication": 11, "volume": "170", "yearOfPublication": 1999, "journalIssueId": 977776, "issue": "2", "dateOfPublication": "1999 Nov"}}, "20800516": {"pubYear": "2010", "dateOfCreation": "2010-09-20", "pubModel": "Print-Electronic", "chemicalList": {"chemical": [{"registryNumber": "EC 1.15.1.1", "name": "Superoxide Dismutase"}, {"registryNumber": "11062-77-4", "name": "Superoxides"}, {"registryNumber": "0", "name": "Oncogene Proteins"}, {"registryNumber": "EC 1.15.1.1", "name": "superoxide dismutase 2"}, {"registryNumber": "EC 1.11.1.15", "name": "DJ-1 protein, mouse"}]}, "authorString": "Xu X, Martin F, Friedman JS.", "affiliation": "Department of Molecular and Experimental Medicine, The Scripps Research Institute La Jolla, California 92037, USA.", "pubTypeList": {"pubType": ["Journal Article", "Research Support, N.I.H., Extramural"]}, "grantsList": {"grant": [{"acronym": "DK", "orderIn": 0, "agency": "NIDDK NIH HHS", "grantId": "R21DK075763"}]}, "hasPDF": "Y", "id": "20800516", "inEPMC": "Y", "authorList": {"author": [{"affiliation": "Department of Molecular and Experimental Medicine, The Scripps Research Institute La Jolla, California 92037, USA.", "fullName": "Xu X", "initials": "X", "firstName": "Xiuling", "lastName": "Xu"}, {"lastName": "Martin", "fullName": "Martin F", "firstName": "Florent", "initials": "F"}, {"lastName": "Friedman", "fullName": "Friedman JS", "firstName": "Jeffrey S", "initials": "JS"}]}, "title": "The familial Parkinson's disease gene DJ-1 (PARK7) is expressed in red cells and plays a role in protection against oxidative damage.", "hasSuppl": "N", "citedByCount": 8, "source": "MED", "pmid": "20800516", "hasLabsLinks": "N", "subsetList": {"subset": [{"code": "IM", "name": "Index Medicus"}]}, "meshHeadingList": {"meshHeading": [{"descriptorName": "Erythrocytes", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Cell Line, Tumor", "majorTopic_YN": "N"}, {"descriptorName": "Mitochondria", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Animals", "majorTopic_YN": "N"}, {"descriptorName": "Mice, Knockout", "majorTopic_YN": "N"}, {"descriptorName": "Mice", "majorTopic_YN": "N"}, {"descriptorName": "Superoxides", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Superoxide Dismutase", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Oncogene Proteins", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "BI", "qualifierName": "biosynthesis", "majorTopic_YN": "Y"}, {"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}]}}, {"descriptorName": "Gene Expression Profiling", "majorTopic_YN": "N"}, {"descriptorName": "Cell Survival", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PH", "qualifierName": "physiology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Up-Regulation", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PH", "qualifierName": "physiology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Oxidative Stress", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PH", "qualifierName": "physiology", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Erythroid Precursor Cells", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}]}, "inPMC": "Y", "dbCrossReferenceList": {"dbName": ["UNIPROT"]}, "hasTMAccessionNumbers": "N", "hasReferences": "N", "firstPublicationDate": "2010-08-30", "doi": "10.1016/j.bcmd.2010.07.014", "isOpenAccess": "N", "pageInfo": "227-232", "pmcid": "PMC2962440", "hasDbCrossReferences": "Y", "abstractText": "The antioxidant enzyme manganese superoxide dismutase (SOD2) serves as the primary defense against mitochondrial superoxide. Impaired SOD2 activity in murine hematopoietic cells affects erythroid development, resulting in anemia characterized by intra-mitochondrial iron deposition, reticulocytosis and shortened red cell life span. Gene expression profiling of normal and SOD2 deficient erythroblasts identified the Parkinson's disease locus DJ-1 (Park7) as a differentially expressed transcript. To investigate the role of DJ-1 in hematopoietic cell development and protection against oxidative stress caused by Sod2 loss, we evaluated red cell parameters, reticulocyte count, red cell turnover and reactive oxygen species production in DJ-1 knockout animals and chimeric animals lacking both SOD2 and DJ-1 in hematopoietic cells generated by fetal liver transplantation. We also investigated DJ-1 protein expression in primary murine erythroid and erythroleukemia cells (MEL). Loss of DJ-1 exacerbates the phenotype of SOD2 deficiency, increasing reticulocyte count and decreasing red cell survival. Using MEL cells, we show that DJ-1 is up-regulated at the protein level during erythroid differentiation. These results indicate that DJ-1 plays a physiologic role in protection of erythroid cells from oxidant damage, a function unmasked in the context of oxidative stress.", "electronicPublicationDate": "2010-08-30", "language": "eng", "dateOfCompletion": "2010-12-30", "fullTextUrlList": {"fullTextUrl": [{"url": "http://europepmc.org/articles/PMC2962440?pdf=render", "documentStyle": "pdf", "availability": "Free", "availabilityCode": "F", "site": "Europe_PMC"}, {"url": "http://europepmc.org/articles/PMC2962440", "documentStyle": "html", "availability": "Free", "availabilityCode": "F", "site": "Europe_PMC"}, {"url": "http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=EBI&pubmedid=20800516&action=stream&blobtype=pdf", "documentStyle": "pdf", "availability": "Free", "availabilityCode": "F", "site": "PubMedCentral"}, {"url": "http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=EBI&pubmedid=20800516", "documentStyle": "html", "availability": "Free", "availabilityCode": "F", "site": "PubMedCentral"}, {"url": "http://dx.doi.org/10.1016/j.bcmd.2010.07.014", "documentStyle": "doi", "availability": "Subscription required", "availabilityCode": "S", "site": "DOI"}]}, "hasTextMinedTerms": "Y", "dateOfRevision": "2015-03-13", "hasBook": "N", "journalInfo": {"printPublicationDate": "2010-10-01", "journal": {"medlineAbbreviation": "Blood Cells Mol Dis", "isoabbreviation": "Blood Cells Mol. Dis.", "title": "Blood cells, molecules & diseases", "issn": "1079-9796", "nlmid": "9509932", "essn": "1096-0961"}, "monthOfPublication": 10, "volume": "45", "yearOfPublication": 2010, "journalIssueId": 1762998, "issue": "3", "dateOfPublication": "2010 Oct"}}, "22723845": {"pubYear": "2012", "dateOfCreation": "2012-06-22", "pubModel": "Print-Electronic", "chemicalList": {"chemical": [{"registryNumber": "50673-96-6", "name": "dopamine quinone"}, {"registryNumber": "7439-96-5", "name": "Manganese"}, {"registryNumber": "EC 1.15.1.1", "name": "Superoxide Dismutase"}, {"registryNumber": "0", "name": "Reactive Oxygen Species"}, {"registryNumber": "EC 1.15.1.1", "name": "superoxide dismutase 2"}]}, "authorString": "Belluzzi E, Bisaglia M, Lazzarini E, Tabares LC, Beltramini M, Bubacco L.", "affiliation": "Department of Biology, University of Padova, Padova, Italy.", "pubTypeList": {"pubType": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "hasPDF": "Y", "id": "22723845", "inEPMC": "Y", "authorList": {"author": [{"lastName": "Belluzzi", "fullName": "Belluzzi E", "authorId": {"type": "ORCID", "value": "0000-0003-1129-2574"}, "firstName": "Elisa", "initials": "E"}, {"lastName": "Bisaglia", "fullName": "Bisaglia M", "firstName": "Marco", "initials": "M"}, {"lastName": "Lazzarini", "fullName": "Lazzarini E", "firstName": "Elisabetta", "initials": "E"}, {"lastName": "Tabares", "fullName": "Tabares LC", "firstName": "Leandro C", "initials": "LC"}, {"lastName": "Beltramini", "fullName": "Beltramini M", "firstName": "Mariano", "initials": "M"}, {"lastName": "Bubacco", "fullName": "Bubacco L", "authorId": {"type": "ORCID", "value": "0000-0001-7927-9208"}, "firstName": "Luigi", "initials": "L"}]}, "title": "Human SOD2 modification by dopamine quinones affects enzymatic activity by promoting its aggregation: possible implications for Parkinson's disease.", "hasSuppl": "N", "citedByCount": 14, "source": "MED", "pmid": "22723845", "hasLabsLinks": "N", "subsetList": {"subset": [{"code": "IM", "name": "Index Medicus"}]}, "authorIdList": {"authorId": [{"type": "ORCID", "value": "0000-0003-1129-2574"}, {"type": "ORCID", "value": "0000-0001-7927-9208"}]}, "meshHeadingList": {"meshHeading": [{"descriptorName": "Mitochondria", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Humans", "majorTopic_YN": "N"}, {"descriptorName": "Parkinson Disease", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Manganese", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "CH", "qualifierName": "chemistry", "majorTopic_YN": "N"}]}}, {"descriptorName": "Reactive Oxygen Species", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Dopamine", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AA", "qualifierName": "analogs & derivatives", "majorTopic_YN": "Y"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "PD", "qualifierName": "pharmacology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Superoxide Dismutase", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}, {"abbreviation": "CH", "qualifierName": "chemistry", "majorTopic_YN": "N"}]}}, {"descriptorName": "Enzyme Activation", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}]}}, {"descriptorName": "Catalytic Domain", "majorTopic_YN": "N"}, {"descriptorName": "Protein Binding", "majorTopic_YN": "N"}, {"descriptorName": "Kinetics", "majorTopic_YN": "N"}, {"descriptorName": "Mutation", "majorTopic_YN": "N"}]}, "inPMC": "Y", "hasTMAccessionNumbers": "N", "hasReferences": "Y", "firstPublicationDate": "2012-06-18", "doi": "10.1371/journal.pone.0038026", "isOpenAccess": "Y", "pageInfo": "e38026", "pmcid": "PMC3377658", "hasDbCrossReferences": "N", "abstractText": "Mitochondrial dysfunction and oxidative stress are considered central in dopaminergic neurodegeneration in Parkinson's disease (PD). Oxidative stress occurs when the endogenous antioxidant systems are overcome by the generation of reactive oxygen species (ROS). A plausible source of oxidative stress, which could account for the selective degeneration of dopaminergic neurons, is the redox chemistry of dopamine (DA) and leads to the formation of ROS and reactive dopamine-quinones (DAQs). Superoxide dismutase 2 (SOD2) is a mitochondrial enzyme that converts superoxide radicals to molecular oxygen and hydrogen peroxide, providing a first line of defense against ROS. We investigated the possible interplay between DA and SOD2 in the pathogenesis of PD using enzymatic essays, site-specific mutagenesis, and optical and high-field-cw-EPR spectroscopies. Using radioactive DA, we demonstrated that SOD2 is a target of DAQs. Exposure to micromolar DAQ concentrations induces a loss of up to 50% of SOD2 enzymatic activity in a dose-dependent manner, which is correlated to the concomitant formation of protein aggregates, while the coordination geometry of the active site appears unaffected by DAQ modifications. Our findings support a model in which DAQ-mediated SOD2 inactivation increases mitochondrial ROS production, suggesting a link between oxidative stress and mitochondrial dysfunction.", "electronicPublicationDate": "2012-06-18", "language": "eng", "dateOfCompletion": "2012-12-12", "fullTextUrlList": {"fullTextUrl": [{"url": "http://europepmc.org/articles/PMC3377658?pdf=render", "documentStyle": "pdf", "availability": "Open access", "availabilityCode": "OA", "site": "Europe_PMC"}, {"url": "http://europepmc.org/articles/PMC3377658", "documentStyle": "html", "availability": "Open access", "availabilityCode": "OA", "site": "Europe_PMC"}, {"url": "http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=EBI&pubmedid=22723845&action=stream&blobtype=pdf", "documentStyle": "pdf", "availability": "Free", "availabilityCode": "F", "site": "PubMedCentral"}, {"url": "http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=EBI&pubmedid=22723845", "documentStyle": "html", "availability": "Free", "availabilityCode": "F", "site": "PubMedCentral"}, {"url": "http://dx.doi.org/10.1371/journal.pone.0038026", "documentStyle": "doi", "availability": "Subscription required", "availabilityCode": "S", "site": "DOI"}]}, "hasTextMinedTerms": "Y", "dateOfRevision": "2013-07-12", "hasBook": "N", "journalInfo": {"printPublicationDate": "2012-01-01", "journal": {"title": "PloS one", "medlineAbbreviation": "PLoS One", "isoabbreviation": "PLoS ONE", "nlmid": "101285081", "essn": "1932-6203"}, "monthOfPublication": 0, "volume": "7", "yearOfPublication": 2012, "journalIssueId": 1937981, "issue": "6", "dateOfPublication": "2012 "}}}, "HSPB1": {"22566955": {"pubYear": "2012", "dateOfCreation": "2012-05-08", "pubModel": "Electronic-eCollection", "authorString": "Brownell SE, Becker RA, Steinman L.", "affiliation": "Department of Neurology and Neurological Sciences, Stanford University Stanford, CA, USA.", "pubTypeList": {"pubType": ["Journal Article"]}, "id": "22566955", "inEPMC": "Y", "authorList": {"author": [{"lastName": "Brownell", "fullName": "Brownell SE", "firstName": "Sara E", "initials": "SE"}, {"lastName": "Becker", "fullName": "Becker RA", "firstName": "Rachel A", "initials": "RA"}, {"lastName": "Steinman", "fullName": "Steinman L", "firstName": "Lawrence", "initials": "L"}]}, "title": "The protective and therapeutic function of small heat shock proteins in neurological diseases.", "hasSuppl": "N", "citedByCount": 5, "source": "MED", "pmid": "22566955", "hasLabsLinks": "Y", "hasTextMinedTerms": "Y", "hasPDF": "Y", "inPMC": "Y", "hasTMAccessionNumbers": "N", "hasReferences": "Y", "firstPublicationDate": "2012-05-01", "language": "eng", "doi": "10.3389/fimmu.2012.00074", "isOpenAccess": "Y", "pageInfo": "74", "pmcid": "PMC3342061", "hasDbCrossReferences": "N", "keywordList": {"keyword": ["sHSPs", "neuroinflammation", "Neurological Diseases", "Hspb1", "Small Heat Shock Proteins", "Hspb5"]}, "abstractText": "Historically, small heat shock proteins (sHSPs) have been extensively studied in the context of being intracellular molecular chaperones. However, recent studies looking at the role of sHSPs in neurological diseases have demonstrated a near universal upregulation of certain sHSPs in damaged and diseased brains. Initially, it was thought that sHSPs are pathological in these disease states because they are found in the areas of damage. However, transgenic overexpression and exogenous administration of sHSPs in various experimental disease paradigms have shown just the contrary - that sHSPs are protective, not pathological. This review examines sHSPs in neurological diseases and highlights the potential for using these neuroprotective sHSPs as novel therapeutics. It first addresses the endogenous expression of sHSPs in a variety of neurological disorders. Although many studies have examined the expression of sHSPs in neurological diseases, there are no review articles summarizing these data. Furthermore, it focuses on recent studies that have investigated the therapeutic potential of sHSPs for neurological diseases. Finally, it will explain what we think is the function of endogenous sHSPs in neurological diseases.", "electronicPublicationDate": "2012-05-01", "license": "cc by-nc", "dateOfCompletion": "2012-08-23", "fullTextUrlList": {"fullTextUrl": [{"url": "http://europepmc.org/articles/PMC3342061?pdf=render", "documentStyle": "pdf", "availability": "Open access", "availabilityCode": "OA", "site": "Europe_PMC"}, {"url": "http://europepmc.org/articles/PMC3342061", "documentStyle": "html", "availability": "Open access", "availabilityCode": "OA", "site": "Europe_PMC"}, {"url": "http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=EBI&pubmedid=22566955", "documentStyle": "html", "availability": "Free", "availabilityCode": "F", "site": "PubMedCentral"}, {"url": "http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=EBI&pubmedid=22566955&action=stream&blobtype=pdf", "documentStyle": "pdf", "availability": "Free", "availabilityCode": "F", "site": "PubMedCentral"}, {"url": "http://dx.doi.org/10.3389/fimmu.2012.00074", "documentStyle": "doi", "availability": "Subscription required", "availabilityCode": "S", "site": "DOI"}]}, "dateOfRevision": "2013-08-13", "hasBook": "N", "journalInfo": {"printPublicationDate": "2012-01-01", "journal": {"title": "Frontiers in immunology", "medlineAbbreviation": "Front Immunol", "isoabbreviation": "Front Immunol", "nlmid": "101560960", "essn": "1664-3224"}, "monthOfPublication": 0, "volume": "3", "yearOfPublication": 2012, "journalIssueId": 1929444, "dateOfPublication": "2012 "}}, "26887567": {"pubYear": "2016", "dateOfCreation": "2016-02-18", "pubModel": "Print-Electronic", "authorString": "Oberstadt M, Mitter D, Classen J, Baum P.", "affiliation": "Department of Neurology, University of Leipzig, Liebigstra\u00dfe 20, 04103, Leipzig, Germany.", "pubTypeList": {"pubType": ["Journal Article"]}, "id": "26887567", "inEPMC": "N", "authorList": {"author": [{"affiliation": "Department of Neurology, University of Leipzig, Liebigstra\u00dfe 20, 04103, Leipzig, Germany.", "fullName": "Oberstadt M", "initials": "M", "firstName": "Moritz", "lastName": "Oberstadt"}, {"affiliation": "Institute of Human Genetics, University of Leipzig, Philipp-Rosenthal-Str. 55, 04103, Leipzig.", "fullName": "Mitter D", "initials": "D", "firstName": "Diana", "lastName": "Mitter"}, {"affiliation": "Department of Neurology, University of Leipzig, Liebigstra\u00dfe 20, 04103, Leipzig, Germany.", "fullName": "Classen J", "initials": "J", "firstName": "Joseph", "lastName": "Classen"}, {"affiliation": "Department of Neurology, University of Leipzig, Liebigstra\u00dfe 20, 04103, Leipzig, Germany.", "fullName": "Baum P", "initials": "P", "firstName": "Petra", "lastName": "Baum"}]}, "title": "Late onset dHMN II caused by c.404C>G mutation in HSPB1 gene.", "citedByCount": 0, "source": "MED", "pmid": "26887567", "hasLabsLinks": "Y", "hasTextMinedTerms": "N", "hasPDF": "N", "inPMC": "N", "hasTMAccessionNumbers": "N", "hasReferences": "N", "firstPublicationDate": "2016-02-17", "doi": "10.1111/jns.12165", "isOpenAccess": "N", "hasDbCrossReferences": "N", "keywordList": {"keyword": ["HSP27", "Parkinson's Disease", "Hereditary Neuropathy", "Hspb1", "Dhmn Ii"]}, "abstractText": "Distal hereditary motor neuropathy (dHMN) type II is genetically heterogeneous. We report 3 siblings of a German family with late onset distal motor neuropathy due to the c.404C>G mutation in heat-shock 27-kDa protein 1 gene (HSPB1/HSP27). A 36-year old mutation carrier, daughter of 1 sibling, did not present any clinical or electrophysiological abnormalities. The index patient (oldest brother) developed weakness of the distal lower limbs and nocturnal muscle cramps at the age of 54 years old. Five years later this patient developed an L-DOPA-responsive hypokinetic rigid syndrome, establishing a diagnosis of Parkinson's disease. Although none of the 3 other mutation carriers displayed Parkinsonian signs, a pathogenic relationship with Parkinson's disease remains a possibility, based on the known molecular pathology of HSPB1. The rare pathogenic HSPB1 c.404C>G mutation may predispose for late-onset of dHMN type II.", "electronicPublicationDate": "2016-02-17", "language": "eng", "fullTextUrlList": {"fullTextUrl": [{"url": "http://dx.doi.org/10.1111/jns.12165", "documentStyle": "doi", "availability": "Subscription required", "availabilityCode": "S", "site": "DOI"}]}, "dateOfRevision": "2016-02-20", "hasBook": "N", "journalInfo": {"printPublicationDate": "2016-02-01", "journal": {"medlineAbbreviation": "J Peripher Nerv Syst", "isoabbreviation": "J. Peripher. Nerv. Syst.", "title": "Journal of the peripheral nervous system : JPNS", "issn": "1085-9489", "nlmid": "9704532", "essn": "1529-8027"}, "monthOfPublication": 2, "yearOfPublication": 2016, "journalIssueId": 2371023, "dateOfPublication": "2016 Feb"}}, "24278676": {"pubYear": "2012", "dateOfCreation": "2013-11-26", "pubModel": "Print-Electronic", "authorString": "Arrigo AP.", "affiliation": "Apoptosis Cancer and Development Laboratory, Lyon Cancer Research Center, INSERM U1052-CNRS UMR5286, Centre L\u00e9on B\u00e9rard, Claude Bernard University Lyon1, 28 Rue Laennec, 69008 Lyon, France.", "pubTypeList": {"pubType": ["Journal Article", "Review"]}, "id": "24278676", "inEPMC": "Y", "authorList": {"author": [{"affiliation": "Apoptosis Cancer and Development Laboratory, Lyon Cancer Research Center, INSERM U1052-CNRS UMR5286, Centre L\u00e9on B\u00e9rard, Claude Bernard University Lyon1, 28 Rue Laennec, 69008 Lyon, France.", "fullName": "Arrigo AP", "initials": "AP", "firstName": "A-P", "lastName": "Arrigo"}]}, "title": "Pathology-dependent effects linked to small heat shock proteins expression: an update.", "hasSuppl": "N", "citedByCount": 0, "source": "MED", "pmid": "24278676", "hasLabsLinks": "N", "hasTextMinedTerms": "Y", "hasPDF": "Y", "inPMC": "Y", "hasTMAccessionNumbers": "N", "hasReferences": "Y", "firstPublicationDate": "2012-10-09", "doi": "10.6064/2012/185641", "isOpenAccess": "Y", "pageInfo": "185641", "pmcid": "PMC3820616", "hasDbCrossReferences": "N", "abstractText": "Small heat shock proteins (small Hsps) are stress-induced molecular chaperones that act as holdases towards polypeptides that have lost their folding in stress conditions or consequently of mutations in their coding sequence. A cellular protection against the deleterious effects mediated by damaged proteins is thus provided to cells. These chaperones are also highly expressed in response to protein conformational and inflammatory diseases and cancer pathologies. Through specific and reversible modifications in their phospho-oligomeric organization, small Hsps can chaperone appropriate client proteins in order to provide cells with resistance to different types of injuries or pathological conditions. By helping cells to better cope with their pathological status, their expression can be either beneficial, such as in diseases characterized by pathological cell degeneration, or deleterious when they are required for tumor cell survival. Moreover, small Hsps are actively released by cells and can act as immunogenic molecules that have dual effects depending on the pathology. The cellular consequences linked to their expression levels and relationships with other Hsps as well as therapeutic strategies are discussed in view of their dynamic structural organization required to interact with specific client polypeptides. ", "electronicPublicationDate": "2012-10-09", "language": "eng", "dateOfCompletion": "2013-11-26", "fullTextUrlList": {"fullTextUrl": [{"url": "http://europepmc.org/articles/PMC3820616?pdf=render", "documentStyle": "pdf", "availability": "Open access", "availabilityCode": "OA", "site": "Europe_PMC"}, {"url": "http://europepmc.org/articles/PMC3820616", "documentStyle": "html", "availability": "Open access", "availabilityCode": "OA", "site": "Europe_PMC"}, {"url": "http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=EBI&pubmedid=24278676&action=stream&blobtype=pdf", "documentStyle": "pdf", "availability": "Free", "availabilityCode": "F", "site": "PubMedCentral"}, {"url": "http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=EBI&pubmedid=24278676", "documentStyle": "html", "availability": "Free", "availabilityCode": "F", "site": "PubMedCentral"}, {"url": "http://dx.doi.org/10.6064/2012/185641", "documentStyle": "doi", "availability": "Subscription required", "availabilityCode": "S", "site": "DOI"}]}, "dateOfRevision": "2013-12-16", "hasBook": "N", "journalInfo": {"printPublicationDate": "2012-01-01", "journal": {"title": "Scientifica", "medlineAbbreviation": "Scientifica (Cairo)", "isoabbreviation": "Scientifica (Cairo)", "nlmid": "101589932", "essn": "2090-908X"}, "monthOfPublication": 0, "volume": "2012", "yearOfPublication": 2012, "journalIssueId": 2039552, "dateOfPublication": "2012 "}}}, "CALR": {"23771339": {"pubYear": "2013", "dateOfCreation": "2013-06-26", "pubModel": "Print-Electronic", "chemicalList": {"chemical": [{"registryNumber": "0", "name": "AIF1 protein, human"}, {"registryNumber": "0", "name": "Nerve Tissue Proteins"}, {"registryNumber": "0", "name": "DNA-Binding Proteins"}, {"registryNumber": "0", "name": "Calcium-Binding Proteins"}, {"registryNumber": "0", "name": "Calcium Channels, L-Type"}]}, "authorString": "Hurley MJ, Brandon B, Gentleman SM, Dexter DT.", "affiliation": "Centre for Neuroinflammation and Neurodegeneration, Division of Brain Sciences, Imperial College, London, W12 0NN, UK. m.hurley@imperial.ac.uk", "pubTypeList": {"pubType": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "grantsList": {"grant": [{"orderIn": 0, "agency": "Parkinson's UK", "grantId": "G-0909"}]}, "hasPDF": "N", "id": "23771339", "inEPMC": "N", "authorList": {"author": [{"firstName": "Michael J", "lastName": "Hurley", "affiliation": "Centre for Neuroinflammation and Neurodegeneration, Division of Brain Sciences, Imperial College, London, W12 0NN, UK. m.hurley@imperial.ac.uk", "authorId": {"type": "ORCID", "value": "0000-0001-8022-9283"}, "fullName": "Hurley MJ", "initials": "MJ"}, {"lastName": "Brandon", "fullName": "Brandon B", "firstName": "Bianca", "initials": "B"}, {"lastName": "Gentleman", "fullName": "Gentleman SM", "firstName": "Steve M", "initials": "SM"}, {"lastName": "Dexter", "fullName": "Dexter DT", "firstName": "David T", "initials": "DT"}]}, "title": "Parkinson's disease is associated with altered expression of CaV1 channels and calcium-binding proteins.", "citedByCount": 22, "pageInfo": "2077-2097", "source": "MED", "pmid": "23771339", "hasLabsLinks": "Y", "subsetList": {"subset": [{"code": "AIM", "name": "Core clinical journals"}, {"code": "IM", "name": "Index Medicus"}]}, "authorIdList": {"authorId": [{"type": "ORCID", "value": "0000-0001-8022-9283"}]}, "meshHeadingList": {"meshHeading": [{"descriptorName": "Brain", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Spinal Cord", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Neurons", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Humans", "majorTopic_YN": "N"}, {"descriptorName": "Parkinson Disease", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Calcium-Binding Proteins", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Calcium Channels, L-Type", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}, {"descriptorName": "DNA-Binding Proteins", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Nerve Tissue Proteins", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Stereotaxic Techniques", "majorTopic_YN": "N"}, {"descriptorName": "Densitometry", "majorTopic_YN": "N"}, {"descriptorName": "Cell Count", "majorTopic_YN": "N"}, {"descriptorName": "Analysis of Variance", "majorTopic_YN": "N"}, {"descriptorName": "Aged", "majorTopic_YN": "N"}, {"descriptorName": "Aged, 80 and over", "majorTopic_YN": "N"}, {"descriptorName": "Middle Aged", "majorTopic_YN": "N"}, {"descriptorName": "Female", "majorTopic_YN": "N"}, {"descriptorName": "Male", "majorTopic_YN": "N"}]}, "inPMC": "N", "dbCrossReferenceList": {"dbName": ["UNIPROT"]}, "hasTMAccessionNumbers": "N", "hasReferences": "Y", "firstPublicationDate": "2013-06-14", "doi": "10.1093/brain/awt134", "isOpenAccess": "N", "commentCorrectionList": {"commentCorrection": [{"source": "MED", "orderIn": 1, "type": "Comment in", "id": "23788521", "reference": "Brain. 2013 Jul;136(Pt 7):2015-6"}]}, "hasDbCrossReferences": "Y", "keywordList": {"keyword": ["Calcium channel", "Calcium-binding proteins", "Dyskinesia", "Parkinson\u2019s Disease", "dihydropyridines"]}, "abstractText": "In Parkinson's disease oxidative stress and calcium-induced excitotoxicity have been considered important mechanisms leading to cell death for decades, but the factors that make some neurons vulnerable to neurodegeneration while others remain resistant are not fully understood. Studies of the disorder in animal models suggest that the voltage-gated calcium channel subtype Ca(V)1.3 has a role in making neurons susceptible to neurodegeneration and support earlier work in post-mortem human brain that suggested loss of calcium buffering capacity in neurons correlated with areas of neuronal loss in the substantia nigra of parkinsonian brain. This study examined expression of Ca(V)1 subtypes and the calcium-binding proteins calbindin, calmodulin and calreticulin in areas vulnerable and resistant to neurodegeneration in Parkinson's disease, in brain from neurologically normal individuals and patients with Parkinson's disease. In control brain the expression of a specific Ca(V)1 subtype or distribution of each calcium-binding protein did not associate with those regions prone to neurodegeneration in Parkinson's disease. Whereas, alterations in the amount of both Ca(V)1 subtypes and the calcium-binding proteins were found throughout the brain in Parkinson's disease. Some changes reflected the cell loss seen in Parkinson's disease, whereas others represented altered levels of cellular expression, which as they occurred in the absence of cell loss could not be explained as solely compensatory to the neurodegeneration. The finding of increased Ca(V)1.3 subtype expression in the cerebral cortex of early stage Parkinson's disease, before the appearance of pathological changes, supports the view that disturbed calcium homeostasis is an early feature of Parkinson's disease and not just a compensatory consequence to the neurodegenerative process. This interpretation is supported further by the finding that the ratio of Ca(V)1 subtypes differed throughout the brain in patients with Parkinson's disease compared with control subjects, in favour of an increased use of Ca(V)1.3, which would add to the metabolic burden for cells that rely on this Ca(V)1 subtype for electrical activity and could therefore render specific neuronal populations more vulnerable to neurodegeneration.", "electronicPublicationDate": "2013-06-14", "language": "eng", "dateOfCompletion": "2013-08-29", "fullTextUrlList": {"fullTextUrl": [{"url": "http://dx.doi.org/10.1093/brain/awt134", "documentStyle": "doi", "availability": "Subscription required", "availabilityCode": "S", "site": "DOI"}]}, "hasTextMinedTerms": "N", "dateOfRevision": "2014-03-19", "hasBook": "N", "journalInfo": {"printPublicationDate": "2013-07-01", "journal": {"medlineAbbreviation": "Brain", "isoabbreviation": "Brain", "title": "Brain : a journal of neurology", "issn": "0006-8950", "nlmid": "0372537", "essn": "1460-2156"}, "monthOfPublication": 7, "volume": "136", "yearOfPublication": 2013, "journalIssueId": 2051586, "issue": "Pt 7", "dateOfPublication": "2013 Jul"}}, "24860980": {"pubYear": "2014", "dateOfCreation": "2014-08-15", "pubModel": "Print-Electronic", "chemicalList": {"chemical": [{"registryNumber": "0", "name": "Adrenergic Agents"}, {"registryNumber": "20350-15-6", "name": "Brefeldin A"}, {"registryNumber": "0", "name": "Calreticulin"}, {"registryNumber": "139873-08-8", "name": "Calnexin"}, {"registryNumber": "EC 5.3.4.1", "name": "Grp58 protein, rat"}, {"registryNumber": "EC 5.3.4.1", "name": "Protein Disulfide-Isomerases"}, {"registryNumber": "0", "name": "Proteasome Inhibitors"}, {"registryNumber": "8HW4YBZ748", "name": "Oxidopamine"}]}, "authorString": "Kuang XL, Liu F, Chen H, Li Y, Liu Y, Xiao J, Shan G, Li M, Snider BJ, Qu J, Barger SW, Wu S.", "affiliation": "School of Optometry and Ophthalmology and Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China; State Key Laboratory Cultivation Base and Key Laboratory of Vision Science, Ministry of Health, Zhejiang Provincial Key Laboratory of Ophthalmology and Optometry, Wenzhou, Zhejiang, People's Republic of China.", "pubTypeList": {"pubType": ["Journal Article", "Research Support, Non-U.S. Gov't", "Research Support, N.I.H., Extramural"]}, "grantsList": {"grant": [{"acronym": "AG", "orderIn": 0, "agency": "NIA NIH HHS", "grantId": "P01AG012411"}, {"acronym": "AG", "orderIn": 0, "agency": "NIA NIH HHS", "grantId": "P01 AG012411"}]}, "hasPDF": "Y", "id": "24860980", "inEPMC": "Y", "authorList": {"author": [{"affiliation": "School of Optometry and Ophthalmology and Eye Hospital, Wenzhou Medical University, Wenzhou, Zhejiang, People's Republic of China; State Key Laboratory Cultivation Base and Key Laboratory of Vision Science, Ministry of Health, Zhejiang Provincial Key Laboratory of Ophthalmology and Optometry, Wenzhou, Zhejiang, People's Republic of China.", "fullName": "Kuang XL", "initials": "XL", "firstName": "Xiu-Li", "lastName": "Kuang"}, {"lastName": "Liu", "fullName": "Liu F", "firstName": "Fang", "initials": "F"}, {"lastName": "Chen", "fullName": "Chen H", "firstName": "Huifang", "initials": "H"}, {"lastName": "Li", "fullName": "Li Y", "firstName": "Yiping", "initials": "Y"}, {"lastName": "Liu", "fullName": "Liu Y", "firstName": "Yimei", "initials": "Y"}, {"lastName": "Xiao", "fullName": "Xiao J", "firstName": "Jian", "initials": "J"}, {"lastName": "Shan", "fullName": "Shan G", "authorId": {"type": "ORCID", "value": "0000-0002-3561-2088"}, "firstName": "Ge", "initials": "G"}, {"lastName": "Li", "fullName": "Li M", "firstName": "Mingjie", "initials": "M"}, {"lastName": "Snider", "fullName": "Snider BJ", "firstName": "B Joy", "initials": "BJ"}, {"lastName": "Qu", "fullName": "Qu J", "firstName": "Jia", "initials": "J"}, {"lastName": "Barger", "fullName": "Barger SW", "firstName": "Steven W", "initials": "SW"}, {"lastName": "Wu", "fullName": "Wu S", "authorId": {"type": "ORCID", "value": "0000-0003-1154-2369"}, "firstName": "Shengzhou", "initials": "S"}]}, "title": "Reductions of the components of the calreticulin/calnexin quality-control system by proteasome inhibitors and their relevance in a rodent model of Parkinson's disease.", "hasSuppl": "N", "citedByCount": 0, "source": "MED", "pmid": "24860980", "hasLabsLinks": "N", "subsetList": {"subset": [{"code": "IM", "name": "Index Medicus"}]}, "authorIdList": {"authorId": [{"type": "ORCID", "value": "0000-0002-3561-2088"}, {"type": "ORCID", "value": "0000-0003-1154-2369"}]}, "meshHeadingList": {"meshHeading": [{"descriptorName": "Neocortex", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "CY", "qualifierName": "cytology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Neurons", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "UL", "qualifierName": "ultrastructure", "majorTopic_YN": "N"}]}}, {"descriptorName": "Cells, Cultured", "majorTopic_YN": "N"}, {"descriptorName": "Endoplasmic Reticulum", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Animals", "majorTopic_YN": "N"}, {"descriptorName": "Animals, Newborn", "majorTopic_YN": "N"}, {"descriptorName": "Rats", "majorTopic_YN": "N"}, {"descriptorName": "Rats, Sprague-Dawley", "majorTopic_YN": "N"}, {"descriptorName": "Parkinson Disease", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "N"}, {"abbreviation": "ET", "qualifierName": "etiology", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Disease Models, Animal", "majorTopic_YN": "N"}, {"descriptorName": "Oxidopamine", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "TO", "qualifierName": "toxicity", "majorTopic_YN": "N"}]}}, {"descriptorName": "Brefeldin A", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PD", "qualifierName": "pharmacology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Calnexin", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Calreticulin", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Adrenergic Agents", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "TO", "qualifierName": "toxicity", "majorTopic_YN": "N"}]}}, {"descriptorName": "Gene Expression Regulation", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Protein Disulfide-Isomerases", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Endoplasmic Reticulum Stress", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}]}}, {"descriptorName": "Proteasome Inhibitors", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PD", "qualifierName": "pharmacology", "majorTopic_YN": "N"}, {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}]}}]}, "inPMC": "N", "hasTMAccessionNumbers": "N", "hasReferences": "Y", "firstPublicationDate": "2014-05-23", "doi": "10.1002/jnr.23413", "isOpenAccess": "N", "pageInfo": "1319-1329", "pmcid": "PMC4412743", "hasDbCrossReferences": "N", "keywordList": {"keyword": ["Chaperone", "Unfolded protein response (UPR)", "Parkinson's Disease", "endoplasmic reticulum stress", "Er Quality Control", "Endoplasmic Reticulum-associated Degradation (Erad)", "Ubiquitin-proteasome System (Ups)", "Calreticulin/calnexin Cycle"]}, "abstractText": "Evidence indicates that the ubiquitin-proteasome system and the endoplasmic retculum (ER) quality-control system work in concert to ensure that proteins are correctly folded in the ER and that misfolded proteins are retrotransported to the cytosol for degradation by proteasomes. Dysfunction of either system results in developmental abnormalities and even death in animals. This study investigates whether and how proteasome inhibition impacts the components of the calreticulin (CRT)/calnexin (CNX) glycoprotein folding machinery, a typical ER protein quality-control system, in the context of early neuronal injury. Here we report that proteasome inhibitor treatments, at nonlethal levels, reduced protein levels of CRT and ERp57 but not of CNX. These treatments increased protein levels of CRT in culture media, an effect blocked by brefeldin A, an inhibitor of protein trafficking; by contrast, ERp57 was not detected in culture media. Knockdown of CRT levels alone increased the vulnerability of SH-SY5Y, a neuronal cell line, to 6-hydroxydopamine (6-OHDA) toxicity. In a rat model of Parkinson's disease, intrastriatal 6-OHDA lesions resulted in decreased levels of CRT and ERp57 in the midbrain. These findings suggest that reduction of the components of CRT/CNX glycoprotein quality-control system may play a role in neuronal injury in Parkinson's disease and other neurodegenerative disorders associated with dysfunction of the ubiquitin-proteasome system.", "electronicPublicationDate": "2014-05-23", "language": "eng", "dateOfCompletion": "2015-05-11", "fullTextUrlList": {"fullTextUrl": [{"url": "http://europepmc.org/articles/PMC4412743?pdf=render", "documentStyle": "pdf", "availability": "Free", "availabilityCode": "F", "site": "Europe_PMC"}, {"url": "http://europepmc.org/articles/PMC4412743", "documentStyle": "html", "availability": "Free", "availabilityCode": "F", "site": "Europe_PMC"}, {"url": "http://dx.doi.org/10.1002/jnr.23413", "documentStyle": "doi", "availability": "Subscription required", "availabilityCode": "S", "site": "DOI"}]}, "hasTextMinedTerms": "Y", "dateOfRevision": "2015-05-13", "hasBook": "N", "journalInfo": {"printPublicationDate": "2014-10-01", "journal": {"medlineAbbreviation": "J Neurosci Res", "isoabbreviation": "J. Neurosci. Res.", "title": "Journal of neuroscience research", "issn": "0360-4012", "nlmid": "7600111", "essn": "1097-4547"}, "monthOfPublication": 10, "volume": "92", "yearOfPublication": 2014, "journalIssueId": 2191687, "issue": "10", "dateOfPublication": "2014 Oct"}}}, "DCC": {"22926168": {"pubYear": "2013", "dateOfCreation": "2012-12-11", "pubModel": "Print-Electronic", "chemicalList": {"chemical": [{"registryNumber": "0", "name": "Otx transcription factors"}, {"registryNumber": "0", "name": "homeobox protein PITX3"}, {"registryNumber": "0", "name": "Receptors, Cell Surface"}, {"registryNumber": "0", "name": "Transcription Factors"}, {"registryNumber": "0", "name": "Tumor Suppressor Proteins"}, {"registryNumber": "0", "name": "Homeodomain Proteins"}, {"registryNumber": "0", "name": "DCC protein, human"}, {"registryNumber": "0", "name": "Dcc protein, mouse"}, {"registryNumber": "0", "name": "Otx2 protein, mouse"}, {"registryNumber": "0", "name": "OTX2 protein, human"}]}, "authorString": "Reyes S, Fu Y, Double KL, Cottam V, Thompson LH, Kirik D, Paxinos G, Watson C, Cooper HM, Halliday GM.", "affiliation": "Neuroscience Research Australia and the School of Medical Sciences, The University of New South Wales, Randwick, Sydney, New South Wales, Australia.", "pubTypeList": {"pubType": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "hasPDF": "N", "id": "22926168", "inEPMC": "N", "authorList": {"author": [{"lastName": "Reyes", "fullName": "Reyes S", "firstName": "Stefanie", "initials": "S"}, {"lastName": "Fu", "fullName": "Fu Y", "firstName": "Yuhong", "initials": "Y"}, {"lastName": "Double", "fullName": "Double KL", "firstName": "Kay L", "initials": "KL"}, {"lastName": "Cottam", "fullName": "Cottam V", "firstName": "Veronica", "initials": "V"}, {"lastName": "Thompson", "fullName": "Thompson LH", "firstName": "Lachlan H", "initials": "LH"}, {"lastName": "Kirik", "fullName": "Kirik D", "firstName": "Deniz", "initials": "D"}, {"lastName": "Paxinos", "fullName": "Paxinos G", "firstName": "George", "initials": "G"}, {"lastName": "Watson", "fullName": "Watson C", "firstName": "Charles", "initials": "C"}, {"lastName": "Cooper", "fullName": "Cooper HM", "firstName": "Helen M", "initials": "HM"}, {"lastName": "Halliday", "fullName": "Halliday GM", "authorId": {"type": "ORCID", "value": "0000-0003-0422-8398"}, "firstName": "Glenda M", "initials": "GM"}]}, "title": "Trophic factors differentiate dopamine neurons vulnerable to Parkinson's disease.", "citedByCount": 2, "source": "MED", "pmid": "22926168", "hasLabsLinks": "Y", "subsetList": {"subset": [{"code": "IM", "name": "Index Medicus"}]}, "authorIdList": {"authorId": [{"type": "ORCID", "value": "0000-0003-0422-8398"}]}, "meshHeadingList": {"meshHeading": [{"descriptorName": "Substantia Nigra", "majorTopic_YN": "Y", "meshQualifierList": {"meshQualifier": [{"abbreviation": "CY", "qualifierName": "cytology", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Ventral Tegmental Area", "majorTopic_YN": "Y", "meshQualifierList": {"meshQualifier": [{"abbreviation": "CY", "qualifierName": "cytology", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Animals", "majorTopic_YN": "N"}, {"descriptorName": "Humans", "majorTopic_YN": "N"}, {"descriptorName": "Mice", "majorTopic_YN": "N"}, {"descriptorName": "Parkinson Disease", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ET", "qualifierName": "etiology", "majorTopic_YN": "Y"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Homeodomain Proteins", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Receptors, Cell Surface", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Tumor Suppressor Proteins", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Transcription Factors", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Gene Expression Profiling", "majorTopic_YN": "N"}, {"descriptorName": "Aging", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Adult", "majorTopic_YN": "N"}, {"descriptorName": "Aged", "majorTopic_YN": "N"}, {"descriptorName": "Aged, 80 and over", "majorTopic_YN": "N"}, {"descriptorName": "Middle Aged", "majorTopic_YN": "N"}, {"descriptorName": "Female", "majorTopic_YN": "N"}, {"descriptorName": "Male", "majorTopic_YN": "N"}, {"descriptorName": "Otx Transcription Factors", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Dopaminergic Neurons", "majorTopic_YN": "Y", "meshQualifierList": {"meshQualifier": [{"abbreviation": "CY", "qualifierName": "cytology", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}]}, "inPMC": "N", "hasTMAccessionNumbers": "N", "hasReferences": "Y", "firstPublicationDate": "2012-08-24", "doi": "10.1016/j.neurobiolaging.2012.07.019", "isOpenAccess": "N", "pageInfo": "873-886", "hasDbCrossReferences": "N", "abstractText": "Recent studies suggest a variety of factors characterize substantia nigra neurons vulnerable to Parkinson's disease, including the transcription factors pituitary homeobox 3 (Pitx3) and orthodenticle homeobox 2 (Otx2) and the trophic factor receptor deleted in colorectal cancer (DCC), but there is limited information on their expression and localization in adult humans. Pitx3, Otx2, and DCC were immunohistochemically localized in the upper brainstem of adult humans and mice and protein expression assessed using relative intensity measures and online microarray data. Pitx3 was present and highly expressed in most dopamine neurons. Surprisingly, in our elderly subjects no Otx2 immunoreactivity was detected in dopamine neurons, although Otx2 gene expression was found in younger cases. Enhanced DCC gene expression occurred in the substantia nigra, and higher amounts of DCC protein characterized vulnerable ventral nigral dopamine neurons. Our data show that, at the age when Parkinson's disease typically occurs, there are no significant differences in the expression of transcription factors in brainstem dopamine neurons, but those most vulnerable to Parkinson's disease rely more on the trophic factor receptor DCC than other brainstem dopamine neurons.", "electronicPublicationDate": "2012-08-24", "language": "eng", "dateOfCompletion": "2013-05-24", "fullTextUrlList": {"fullTextUrl": [{"url": "http://dx.doi.org/10.1016/j.neurobiolaging.2012.07.019", "documentStyle": "doi", "availability": "Subscription required", "availabilityCode": "S", "site": "DOI"}]}, "hasTextMinedTerms": "N", "hasBook": "N", "journalInfo": {"printPublicationDate": "2013-03-01", "journal": {"medlineAbbreviation": "Neurobiol Aging", "isoabbreviation": "Neurobiol. Aging", "title": "Neurobiology of aging", "issn": "0197-4580", "nlmid": "8100437", "essn": "1558-1497"}, "monthOfPublication": 3, "volume": "34", "yearOfPublication": 2013, "journalIssueId": 1992616, "issue": "3", "dateOfPublication": "2013 Mar"}}, "15730872": {"pubYear": "2005", "dateOfCreation": "2005-02-25", "pubModel": "Print", "chemicalList": {"chemical": [{"registryNumber": "0", "name": "calbindin"}, {"registryNumber": "158651-98-0", "name": "netrin-1"}, {"registryNumber": "51-61-6", "name": "Dopamine"}, {"registryNumber": "EC 1.14.16.2", "name": "Tyrosine 3-Monooxygenase"}, {"registryNumber": "0", "name": "Receptors, Cell Surface"}, {"registryNumber": "0", "name": "Nerve Growth Factors"}, {"registryNumber": "0", "name": "Cell Adhesion Molecules"}, {"registryNumber": "0", "name": "Calcium-Binding Protein, Vitamin D-Dependent"}, {"registryNumber": "0", "name": "Receptors, Opioid, mu"}, {"registryNumber": "0", "name": "Tumor Suppressor Proteins"}, {"registryNumber": "0", "name": "Dcc protein, mouse"}]}, "authorString": "Osborne PB, Halliday GM, Cooper HM, Keast JR.", "affiliation": "Prince of Wales Medical Research Institute, University of New South Wales, Barker Street Randwick, Sydney NSW 2031, Australia. p.osborne@usyd.edu.au", "pubTypeList": {"pubType": ["Journal Article", "Research Support, Non-U.S. Gov't", "Comparative Study"]}, "hasPDF": "N", "id": "15730872", "inEPMC": "N", "authorList": {"author": [{"lastName": "Osborne", "fullName": "Osborne PB", "authorId": {"type": "ORCID", "value": "0000-0002-8458-4159"}, "initials": "PB"}, {"lastName": "Halliday", "fullName": "Halliday GM", "authorId": {"type": "ORCID", "value": "0000-0003-0422-8398"}, "initials": "GM"}, {"lastName": "Cooper", "fullName": "Cooper HM", "initials": "HM"}, {"lastName": "Keast", "fullName": "Keast JR", "initials": "JR"}]}, "title": "Localization of immunoreactivity for deleted in colorectal cancer (DCC), the receptor for the guidance factor netrin-1, in ventral tier dopamine projection pathways in adult rodents.", "citedByCount": 31, "source": "MED", "pmid": "15730872", "hasLabsLinks": "N", "subsetList": {"subset": [{"code": "IM", "name": "Index Medicus"}]}, "authorIdList": {"authorId": [{"type": "ORCID", "value": "0000-0002-8458-4159"}, {"type": "ORCID", "value": "0000-0003-0422-8398"}]}, "meshHeadingList": {"meshHeading": [{"descriptorName": "Brain", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "CY", "qualifierName": "cytology", "majorTopic_YN": "Y"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Neural Pathways", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Neurons", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Animals", "majorTopic_YN": "N"}, {"descriptorName": "Mice, Inbred C57BL", "majorTopic_YN": "N"}, {"descriptorName": "Mice", "majorTopic_YN": "N"}, {"descriptorName": "Rats", "majorTopic_YN": "N"}, {"descriptorName": "Rats, Wistar", "majorTopic_YN": "N"}, {"descriptorName": "Dopamine", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Tyrosine 3-Monooxygenase", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Nerve Growth Factors", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Calcium-Binding Protein, Vitamin D-Dependent", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Cell Adhesion Molecules", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Receptors, Cell Surface", "majorTopic_YN": "N"}, {"descriptorName": "Receptors, Opioid, mu", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Tumor Suppressor Proteins", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Fluorescent Antibody Technique", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "MT", "qualifierName": "methods", "majorTopic_YN": "N"}]}}, {"descriptorName": "Gene Expression Regulation", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PH", "qualifierName": "physiology", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Male", "majorTopic_YN": "N"}]}, "inPMC": "N", "dbCrossReferenceList": {"dbName": ["UNIPROT"]}, "hasTMAccessionNumbers": "N", "hasReferences": "Y", "firstPublicationDate": "2005-01-01", "doi": "10.1016/j.neuroscience.2004.11.043", "isOpenAccess": "N", "pageInfo": "671-681", "hasDbCrossReferences": "Y", "abstractText": "DCC (deleted in colorectal cancer)-the receptor of the netrin-1 neuronal guidance factor-is expressed and is active in the central nervous system (CNS) during development, but is down-regulated during maturation. The substantia nigra contains the highest level of netrin-1 mRNA in the adult rodent brain, and corresponding mRNA for DCC has also been detected in this region but has not been localized to any particular neuron type. In this study, an antibody raised against DCC was used to determine if the protein was expressed by adult dopamine neurons, and identify their distribution and projections. Significant DCC-immunoreactivity was detected in midbrain, where it was localized to ventrally displaced A9 dopamine neurons in the substantia nigra, and ventromedial A10 dopamine neurons predominantly situated in and around the interfascicular nucleus. Strong immunoreactivity was not detected in dopamine neurons found elsewhere, or in non-dopamine-containing neurons in the midbrain. Terminal fields selectively labeled with DCC antibody corresponded to known nigrostriatal projections to the dorsolateral striatal patches and dorsomedial shell of the accumbens, and were also detected in prefrontal cortex, septum, lateral habenular and ventral pallidum. The unique distribution of DCC-immunoreactivity in adult ventral midbrain dopamine neurons suggests that netrin-1/DCC signaling could function in plasticity and remodeling previously identified in dopamine projection pathways. In particular, a recent report that DCC is regulated through the ubiquitin-proteosome system via Siah/Sina proteins, is consistent with a potential involvement in genetic and sporadic forms of Parkinson's disease.", "language": "eng", "dateOfCompletion": "2005-06-06", "fullTextUrlList": {"fullTextUrl": [{"url": "http://dx.doi.org/10.1016/j.neuroscience.2004.11.043", "documentStyle": "doi", "availability": "Subscription required", "availabilityCode": "S", "site": "ScienceDirect"}]}, "hasTextMinedTerms": "N", "dateOfRevision": "2006-11-15", "hasBook": "N", "journalInfo": {"printPublicationDate": "2005-01-01", "journal": {"medlineAbbreviation": "Neuroscience", "isoabbreviation": "Neuroscience", "title": "Neuroscience", "issn": "0306-4522", "nlmid": "7605074", "essn": "1873-7544"}, "monthOfPublication": 0, "volume": "131", "yearOfPublication": 2005, "journalIssueId": 1220671, "issue": "3", "dateOfPublication": "2005 "}}, "22748019": {"pubYear": "2012", "dateOfCreation": "2012-07-30", "pubModel": "Electronic", "chemicalList": {"chemical": [{"registryNumber": "0", "name": "netrin receptors"}, {"registryNumber": "0", "name": "Pbx1 protein, mouse"}, {"registryNumber": "0", "name": "Receptors, Cell Surface"}, {"registryNumber": "0", "name": "Transcription Factors"}, {"registryNumber": "0", "name": "Tumor Suppressor Proteins"}, {"registryNumber": "0", "name": "Homeodomain Proteins"}, {"registryNumber": "0", "name": "Dcc protein, mouse"}]}, "authorString": "Sgad\u00f2 P, Ferretti E, Grbec D, Bozzi Y, Simon HH.", "affiliation": "Laboratory of Molecular Neuropathology, Centre for Integrative Biology, University of Trento, Trento, Italy. sgado@science.unitn.it", "pubTypeList": {"pubType": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "hasPDF": "Y", "id": "22748019", "inEPMC": "Y", "authorList": {"author": [{"lastName": "Sgad\u00f2", "fullName": "Sgad\u00f2 P", "authorId": {"type": "ORCID", "value": "0000-0002-4963-8473"}, "firstName": "Paola", "initials": "P"}, {"lastName": "Ferretti", "fullName": "Ferretti E", "firstName": "Elisabetta", "initials": "E"}, {"lastName": "Grbec", "fullName": "Grbec D", "firstName": "Daniel", "initials": "D"}, {"lastName": "Bozzi", "fullName": "Bozzi Y", "firstName": "Yuri", "initials": "Y"}, {"lastName": "Simon", "fullName": "Simon HH", "firstName": "Horst H", "initials": "HH"}]}, "title": "The atypical homeoprotein Pbx1a participates in the axonal pathfinding of mesencephalic dopaminergic neurons.", "hasSuppl": "N", "citedByCount": 9, "source": "MED", "pmid": "22748019", "hasLabsLinks": "Y", "subsetList": {"subset": [{"code": "IM", "name": "Index Medicus"}]}, "authorIdList": {"authorId": [{"type": "ORCID", "value": "0000-0002-4963-8473"}]}, "meshHeadingList": {"meshHeading": [{"descriptorName": "Mesencephalon", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "CY", "qualifierName": "cytology", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Axons", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Animals", "majorTopic_YN": "N"}, {"descriptorName": "Mice, Inbred C57BL", "majorTopic_YN": "N"}, {"descriptorName": "Animals, Newborn", "majorTopic_YN": "N"}, {"descriptorName": "Mice, Knockout", "majorTopic_YN": "N"}, {"descriptorName": "Mice", "majorTopic_YN": "N"}, {"descriptorName": "Homeodomain Proteins", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Receptors, Cell Surface", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Tumor Suppressor Proteins", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Transcription Factors", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Gene Expression Regulation, Developmental", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "PH", "qualifierName": "physiology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Dopaminergic Neurons", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}]}, "inPMC": "Y", "dbCrossReferenceList": {"dbName": ["UNIPROT"]}, "hasTMAccessionNumbers": "N", "hasReferences": "Y", "firstPublicationDate": "2012-07-02", "language": "eng", "doi": "10.1186/1749-8104-7-24", "isOpenAccess": "Y", "pageInfo": "24", "pmcid": "PMC3407702", "hasDbCrossReferences": "Y", "abstractText": " BACKGROUND: The pre B-cell leukemia transcription factor 1 (Pbx1) genes belong to the three amino acid loop extension family of homeodomain proteins that form hetero-oligomeric complexes with other homeodomain transcription factors, thereby modulating target specificity, DNA binding affinity and transcriptional activity of their molecular associates. RESULTS: Here, we provide evidence that Pbx1 is expressed in mesencephalic dopaminergic neurons from embryonic day 11 into adulthood and determines some of the cellular properties of this neuronal population. In Pbx1-deficient mice, the mesencephalic dopaminergic axons stall during mid-gestation at the border between di- and telencephalon before entering the ganglionic eminence, leading to a loose organization of the axonal bundle and partial misrouting. In Pbx1-deficient dopaminergic neurons, the high affinity netrin-1 receptor, deleted in colon cancer (DCC), is down-regulated. Interestingly, we found several conserved Pbx1 binding sites in the first intron of DCC, suggesting a direct regulation of DCC transcription by Pbx1. CONCLUSIONS: The expression of Pbx1 in dopaminergic neurons and its regulation of DCC expression make it an important player in defining the axonal guidance of the midbrain dopaminergic neurons, with possible implications for the normal physiology of the nigro-striatal system as well as processes related to the degeneration of neurons during the course of Parkinson's disease.", "electronicPublicationDate": "2012-07-02", "license": "cc by", "dateOfCompletion": "2012-10-16", "fullTextUrlList": {"fullTextUrl": [{"url": "http://europepmc.org/articles/PMC3407702?pdf=render", "documentStyle": "pdf", "availability": "Open access", "availabilityCode": "OA", "site": "Europe_PMC"}, {"url": "http://europepmc.org/articles/PMC3407702", "documentStyle": "html", "availability": "Open access", "availabilityCode": "OA", "site": "Europe_PMC"}, {"url": "http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=EBI&pubmedid=22748019&action=stream&blobtype=pdf", "documentStyle": "pdf", "availability": "Free", "availabilityCode": "F", "site": "PubMedCentral"}, {"url": "http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=EBI&pubmedid=22748019", "documentStyle": "html", "availability": "Free", "availabilityCode": "F", "site": "PubMedCentral"}, {"url": "http://dx.doi.org/10.1186/1749-8104-7-24", "documentStyle": "doi", "availability": "Subscription required", "availabilityCode": "S", "site": "DOI"}]}, "hasTextMinedTerms": "Y", "dateOfRevision": "2013-07-12", "hasBook": "N", "journalInfo": {"printPublicationDate": "2012-01-01", "journal": {"title": "Neural development", "medlineAbbreviation": "Neural Dev", "isoabbreviation": "Neural Dev", "nlmid": "101286574", "essn": "1749-8104"}, "monthOfPublication": 0, "volume": "7", "yearOfPublication": 2012, "journalIssueId": 1908906, "dateOfPublication": "2012 "}}}, "PPARD": {"26160761": {"pubYear": "2016", "dateOfCreation": "2016-07-08", "pubModel": "Print-Electronic", "authorString": "Tong Q, Wu L, Gao Q, Ou Z, Zhu D, Zhang Y.", "affiliation": "Department of Geriatrics, Huai'an First People's Hospital, Nanjing Medical University, P.O. Box 223300, No. 6 Beijing Road West, Huai'an, People's Republic of China.", "pubTypeList": {"pubType": ["Journal Article"]}, "id": "26160761", "inEPMC": "N", "authorList": {"author": [{"affiliation": "Department of Geriatrics, Huai'an First People's Hospital, Nanjing Medical University, P.O. Box 223300, No. 6 Beijing Road West, Huai'an, People's Republic of China.", "fullName": "Tong Q", "initials": "Q", "firstName": "Qiang", "lastName": "Tong"}, {"affiliation": "Department of Neurology, Nanjing First Hospital, Nanjing Medical University, P.O. Box 210006, No. 68 Changle Road, Nanjing, People's Republic of China.", "fullName": "Wu L", "initials": "L", "firstName": "Liang", "lastName": "Wu"}, {"affiliation": "Department of Neurology, Nanjing First Hospital, Nanjing Medical University, P.O. Box 210006, No. 68 Changle Road, Nanjing, People's Republic of China.", "fullName": "Gao Q", "initials": "Q", "firstName": "Qing", "lastName": "Gao"}, {"affiliation": "Department of Neurology, Nanjing First Hospital, Nanjing Medical University, P.O. Box 210006, No. 68 Changle Road, Nanjing, People's Republic of China.", "fullName": "Ou Z", "initials": "Z", "firstName": "Zhou", "lastName": "Ou"}, {"affiliation": "Department of Pharmacology, School of Pharmacy, Nanjing Medical University, P.O. Box 211166, No. 818 Tianyuan East Road, Jiangning District, Nanjing, People's Republic of China.", "fullName": "Zhu D", "initials": "D", "firstName": "Dongya", "lastName": "Zhu"}, {"affiliation": "Department of Neurology, Nanjing First Hospital, Nanjing Medical University, P.O. Box 210006, No. 68 Changle Road, Nanjing, People's Republic of China. zhangyingdong@aliyun.com.", "fullName": "Zhang Y", "initials": "Y", "firstName": "Yingdong", "lastName": "Zhang"}]}, "title": "PPAR\u03b2/\u03b4 Agonist Provides Neuroprotection by Suppression of IRE1\u03b1-Caspase-12-Mediated Endoplasmic Reticulum Stress Pathway in the Rotenone Rat Model of Parkinson's Disease.", "citedByCount": 0, "source": "MED", "pmid": "26160761", "hasLabsLinks": "N", "subsetList": {"subset": [{"code": "IM", "name": "Index Medicus"}]}, "hasPDF": "N", "inPMC": "N", "hasTMAccessionNumbers": "N", "hasReferences": "Y", "firstPublicationDate": "2015-07-10", "doi": "10.1007/s12035-015-9309-9", "isOpenAccess": "N", "pageInfo": "3822-3831", "hasDbCrossReferences": "N", "keywordList": {"keyword": ["ER stress", "neuroprotection", "Parkinson\u2019s Disease", "Ppar\u03b2/\u03b4"]}, "abstractText": "Two recent studies demonstrated that peroxisome proliferator-activated receptor \u03b2/\u03b4 (PPAR\u03b2/\u03b4) agonists exerted neuroprotective effects in mouse model of Parkinson's disease (PD). However, the underlying mechanisms remain unknown. Endoplasmic reticulum (ER) stress plays a major role in rotenone-induced dopaminergic neuronal degeneration. In the present study, we explored whether GW501516, a selective and high-affinity PPAR\u03b2/\u03b4 agonist, could protect the dopaminergic neurons against degeneration and improve PD behavior via suppressing the ER stress in the rotenone rat model of PD. GW501516 was administered intracerebroventricular infusion. Catalepsy and open field tests were used to test catalepsy and locomotor activities. The levels of dopamine and its metabolites were determined using high-performance liquid chromatography. Western blot and immunohistochemistry analysis were performed to assess dopaminergic neuronal degeneration. Quantitative real-time RT-PCR and Western blot analysis were executed to detect ER stress. TUNEL and immunohistochemistry assays were used to detect ER stress-mediated apoptosis. Our results showed that GW501516 ameliorated the catalepsy symptom and increased locomotor activity. Meanwhile, GW501516 partially reversed the loss of dopaminergic neurons. Moreover, GW501516 suppressed the activation of ER stress markers including inositol-requiring enzyme 1\u03b1 (IRE1\u03b1) and caspase-12. Furthermore, GW501516 inhibited caspase-12-mediated neuronal apoptosis. These findings suggest that GW501516 conferred neuroprotection of not only biochemical and pathological attenuation but also behavioral improvement in the rotenone rat model of PD. More importantly, we demonstrated for the first time that suppressing IRE1\u03b1-caspase-12-mediated ER stress pathway may represent one potential mechanism underlying the neuroprotective effects of PPAR\u03b2/\u03b4 agonist in the rotenone rat model of PD.", "electronicPublicationDate": "2015-07-10", "language": "eng", "fullTextUrlList": {"fullTextUrl": [{"url": "http://dx.doi.org/10.1007/s12035-015-9309-9", "documentStyle": "doi", "availability": "Subscription required", "availabilityCode": "S", "site": "DOI"}]}, "hasTextMinedTerms": "N", "hasBook": "N", "journalInfo": {"printPublicationDate": "2016-08-01", "journal": {"medlineAbbreviation": "Mol Neurobiol", "isoabbreviation": "Mol. Neurobiol.", "title": "Molecular neurobiology", "issn": "0893-7648", "nlmid": "8900963", "essn": "1559-1182"}, "monthOfPublication": 8, "volume": "53", "yearOfPublication": 2016, "journalIssueId": 2427962, "issue": "6", "dateOfPublication": "2016 Aug"}}, "25530507": {"pubYear": "2015", "dateOfCreation": "2015-03-10", "pubModel": "Print", "chemicalList": {"chemical": [{"registryNumber": "0", "name": "Adrenergic Agents"}, {"registryNumber": "0", "name": "Brain-Derived Neurotrophic Factor"}, {"registryNumber": "0", "name": "PPAR gamma"}, {"registryNumber": "0", "name": "PPAR delta"}, {"registryNumber": "0", "name": "PPAR-beta"}, {"registryNumber": "8HW4YBZ748", "name": "Oxidopamine"}]}, "authorString": "Falcone R, Florio TM, Di Giacomo E, Benedetti E, Cristiano L, Antonosante A, Fidoamore A, Massimi M, Alecci M, Ippoliti R, Giordano A, Cimini A.", "affiliation": "Department of Life, Health and\ufeff Environmental Sciences, University of L'Aquila, Italy.", "pubTypeList": {"pubType": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "hasPDF": "N", "id": "25530507", "inEPMC": "N", "authorList": {"author": [{"affiliation": "Department of Life, Health and\ufeff Environmental Sciences, University of L'Aquila, Italy.", "fullName": "Falcone R", "initials": "R", "firstName": "Roberta", "lastName": "Falcone"}, {"lastName": "Florio", "fullName": "Florio TM", "authorId": {"type": "ORCID", "value": "0000-0003-1770-2845"}, "firstName": "Tiziana Marilena", "initials": "TM"}, {"lastName": "Di Giacomo", "fullName": "Di Giacomo E", "firstName": "Erica", "initials": "E"}, {"lastName": "Benedetti", "fullName": "Benedetti E", "firstName": "Elisabetta", "initials": "E"}, {"lastName": "Cristiano", "fullName": "Cristiano L", "firstName": "Loredana", "initials": "L"}, {"lastName": "Antonosante", "fullName": "Antonosante A", "authorId": {"type": "ORCID", "value": "0000-0003-4151-7121"}, "firstName": "Andrea", "initials": "A"}, {"lastName": "Fidoamore", "fullName": "Fidoamore A", "firstName": "Alessia", "initials": "A"}, {"lastName": "Massimi", "fullName": "Massimi M", "firstName": "Mara", "initials": "M"}, {"lastName": "Alecci", "fullName": "Alecci M", "authorId": {"type": "ORCID", "value": "0000-0002-3958-992X"}, "firstName": "Marcello", "initials": "M"}, {"lastName": "Ippoliti", "fullName": "Ippoliti R", "firstName": "Rodolfo", "initials": "R"}, {"lastName": "Giordano", "fullName": "Giordano A", "authorId": {"type": "ORCID", "value": "0000-0002-5959-016X"}, "firstName": "Antonio", "initials": "A"}, {"lastName": "Cimini", "fullName": "Cimini A", "authorId": {"type": "ORCID", "value": "0000-0002-2737-7970"}, "firstName": "Annamaria", "initials": "A"}]}, "title": "PPAR\u03b2/\u03b4 and \u03b3 in a rat model of Parkinson's disease: possible involvement in PD symptoms.", "citedByCount": 0, "source": "MED", "pmid": "25530507", "hasLabsLinks": "Y", "subsetList": {"subset": [{"code": "IM", "name": "Index Medicus"}]}, "authorIdList": {"authorId": [{"type": "ORCID", "value": "0000-0003-1770-2845"}, {"type": "ORCID", "value": "0000-0003-4151-7121"}, {"type": "ORCID", "value": "0000-0002-3958-992X"}, {"type": "ORCID", "value": "0000-0002-5959-016X"}, {"type": "ORCID", "value": "0000-0002-2737-7970"}, {"type": "ORCID", "value": "0000-0003-4151-7121"}]}, "meshHeadingList": {"meshHeading": [{"descriptorName": "Animals", "majorTopic_YN": "N"}, {"descriptorName": "Rats, Sprague-Dawley", "majorTopic_YN": "N"}, {"descriptorName": "Parkinson Disease", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "PP", "qualifierName": "physiopathology", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Disease Models, Animal", "majorTopic_YN": "N"}, {"descriptorName": "Oxidopamine", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"descriptorName": "Brain-Derived Neurotrophic Factor", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "PPAR-beta", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AI", "qualifierName": "antagonists & inhibitors", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}, {"descriptorName": "PPAR delta", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AI", "qualifierName": "antagonists & inhibitors", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}, {"descriptorName": "PPAR gamma", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}, {"abbreviation": "AG", "qualifierName": "agonists", "majorTopic_YN": "N"}]}}, {"descriptorName": "Adrenergic Agents", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AE", "qualifierName": "adverse effects", "majorTopic_YN": "N"}]}}, {"descriptorName": "Male", "majorTopic_YN": "N"}]}, "inPMC": "N", "dbCrossReferenceList": {"dbName": ["UNIPROT"]}, "hasTMAccessionNumbers": "N", "hasReferences": "Y", "firstPublicationDate": "2015-05-01", "doi": "10.1002/jcb.25041", "isOpenAccess": "N", "pageInfo": "844-855", "hasDbCrossReferences": "Y", "keywordList": {"keyword": ["Lipid Peroxidation", "Neurotrophins", "PPARs", "Mood Disorders"]}, "abstractText": "Parkinson's disease is one of the most common neurologic disorder, affecting about 1-4% of persons older than 60 years. Among the proposed mechanisms of PD generation, free radical damage is believed to play a pivotal role in the development and/or progression of the disease. Recently, PPARs, a class of transcription factors involved in several pathways both in physiological and pathological conditions, have been linked by us and others to neurodegeneration. Particularly, PPAR\u03b3 and its ligands have been indicated as potential therapeutic targets for the treatment of several pathological conditions associated with neuroinflammation within the CNS. The anti-inflammatory function of PPAR\u03b3 has attracted attention since agonists exert a broad spectrum of protective effects in several animal models of neurological diseases, including psychiatric diseases. On the other hand a detrimental role for PPAR\u03b2/\u03b4 has been proposed in Alzheimer, being closely related to the decrease of BDNF and Trkfl. On these bases, in this work we used a 6-OHDA hemi-lesioned rat model, inducing loss of dopaminergic neurons, to study the effects of the lesion at three time points from the lesion (1, 2, and 3 weeks), in relevant areas of PD motor symptoms, such as substantia nigra and globus pallidus and in the area of reward and mood control, the nucleus accumbens. In particular, it was studied: (i) the expression of BDNF and its downstream signals; (ii) the modulation of PPARs levels. The results obtained indicate the possible use of a dual PPAR\u03b2/\u03b4 antagonist/PPAR\u03b3 agonist to counteract primary and secondary signs of PD neurodegeneration.", "language": "eng", "dateOfCompletion": "2015-12-08", "fullTextUrlList": {"fullTextUrl": [{"url": "http://dx.doi.org/10.1002/jcb.25041", "documentStyle": "doi", "availability": "Subscription required", "availabilityCode": "S", "site": "DOI"}]}, "hasTextMinedTerms": "N", "hasBook": "N", "journalInfo": {"printPublicationDate": "2015-05-01", "journal": {"medlineAbbreviation": "J Cell Biochem", "isoabbreviation": "J. Cell. Biochem.", "title": "Journal of cellular biochemistry", "issn": "0730-2312", "nlmid": "8205768", "essn": "1097-4644"}, "monthOfPublication": 5, "volume": "116", "yearOfPublication": 2015, "journalIssueId": 2262415, "issue": "5", "dateOfPublication": "2015 May"}}, "22498097": {"pubYear": "2012", "dateOfCreation": "2012-04-24", "pubModel": "Print-Electronic", "chemicalList": {"chemical": [{"registryNumber": "0", "name": "Protease Inhibitors"}, {"registryNumber": "0", "name": "Growth Inhibitors"}, {"registryNumber": "1199-18-4", "name": "Oxidopamine"}, {"registryNumber": "0", "name": "Neuroprotective Agents"}, {"registryNumber": "0", "name": "PPAR gamma"}, {"registryNumber": "0", "name": "PPAR delta"}, {"registryNumber": "EC 3.4.24.17", "name": "Matrix Metalloproteinase 3"}, {"registryNumber": "0", "name": "Matrix Metalloproteinase Inhibitors"}]}, "authorString": "Sadeghian M, Marinova-Mutafchieva L, Broom L, Davis JB, Virley D, Medhurst AD, Dexter DT.", "affiliation": "Parkinson's Disease Research Group, Centre for Neuroscience, Division of Experimental Medicine, Faculty of Medicine, Imperial College London, UK.", "pubTypeList": {"pubType": ["Journal Article", "Research Support, Non-U.S. Gov't", "Comparative Study"]}, "hasPDF": "N", "id": "22498097", "inEPMC": "N", "authorList": {"author": [{"lastName": "Sadeghian", "fullName": "Sadeghian M", "firstName": "M", "initials": "M"}, {"lastName": "Marinova-Mutafchieva", "fullName": "Marinova-Mutafchieva L", "firstName": "L", "initials": "L"}, {"lastName": "Broom", "fullName": "Broom L", "firstName": "L", "initials": "L"}, {"lastName": "Davis", "fullName": "Davis JB", "firstName": "J B", "initials": "JB"}, {"lastName": "Virley", "fullName": "Virley D", "firstName": "D", "initials": "D"}, {"lastName": "Medhurst", "fullName": "Medhurst AD", "firstName": "A D", "initials": "AD"}, {"lastName": "Dexter", "fullName": "Dexter DT", "firstName": "D T", "initials": "DT"}]}, "title": "Full and partial peroxisome proliferation-activated receptor-\u03b3 agonists, but not \u03b4 agonist, rescue of dopaminergic neurons in the 6-OHDA parkinsonian model is associated with inhibition of microglial activation and MMP expression.", "citedByCount": 12, "source": "MED", "pmid": "22498097", "hasLabsLinks": "N", "subsetList": {"subset": [{"code": "IM", "name": "Index Medicus"}]}, "meshHeadingList": {"meshHeading": [{"descriptorName": "Microglia", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}, {"abbreviation": "EN", "qualifierName": "enzymology", "majorTopic_YN": "N"}, {"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Animals", "majorTopic_YN": "N"}, {"descriptorName": "Rats", "majorTopic_YN": "N"}, {"descriptorName": "Rats, Sprague-Dawley", "majorTopic_YN": "N"}, {"descriptorName": "Parkinsonian Disorders", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "CI", "qualifierName": "chemically induced", "majorTopic_YN": "N"}, {"abbreviation": "EN", "qualifierName": "enzymology", "majorTopic_YN": "N"}, {"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Disease Models, Animal", "majorTopic_YN": "N"}, {"descriptorName": "Oxidopamine", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "TO", "qualifierName": "toxicity", "majorTopic_YN": "N"}]}}, {"descriptorName": "Growth Inhibitors", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PD", "qualifierName": "pharmacology", "majorTopic_YN": "Y"}]}}, {"descriptorName": "PPAR delta", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PD", "qualifierName": "pharmacology", "majorTopic_YN": "N"}, {"abbreviation": "AG", "qualifierName": "agonists", "majorTopic_YN": "N"}]}}, {"descriptorName": "PPAR gamma", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PD", "qualifierName": "pharmacology", "majorTopic_YN": "N"}, {"abbreviation": "AG", "qualifierName": "agonists", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Neuroprotective Agents", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PD", "qualifierName": "pharmacology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Protease Inhibitors", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PD", "qualifierName": "pharmacology", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Male", "majorTopic_YN": "N"}, {"descriptorName": "Matrix Metalloproteinase 3", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "BI", "qualifierName": "biosynthesis", "majorTopic_YN": "N"}]}}, {"descriptorName": "Dopaminergic Neurons", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}, {"abbreviation": "EN", "qualifierName": "enzymology", "majorTopic_YN": "N"}, {"abbreviation": "IM", "qualifierName": "immunology", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Matrix Metalloproteinase Inhibitors", "majorTopic_YN": "Y"}]}, "inPMC": "N", "dbCrossReferenceList": {"dbName": ["UNIPROT"]}, "hasTMAccessionNumbers": "N", "hasReferences": "Y", "firstPublicationDate": "2012-04-11", "doi": "10.1016/j.jneuroim.2012.03.010", "isOpenAccess": "N", "pageInfo": "69-77", "hasDbCrossReferences": "Y", "abstractText": " BACKGROUND: Peroxisome proliferator-activated receptor gamma (PPAR\u03b3) is a nuclear hormone receptor that has been shown to have anti-inflammatory and matrix metalloproteinase (MMP) inhibitor properties. PPAR\u03b3 agonists have been shown to have neuroprotective effects in various neurodegeneration models where inflammation is implicated, including models of Parkinson's disease. However, no studies have looked at the effects of partial PPAR\u03b3 agonists. EXPERIMENTAL APPROACH: The neuroprotective effects of the PPAR\u03b3 full agonist, pioglitazone (20 mg/kg), partial PPAR\u03b3 agonist GW855266X (15 mg/kg) and PPAR-\u03b4 full agonist GW610742X (10 mg/kg) were investigated in the 6-hydroxydopamine (6-OHDA) model of Parkinson's disease when administered prior to or post 6-OHDA lesioning. The integrity of the nigrostriatal system was assessed by assessing the numbers dopaminergic neurons in the substantia nigra (SN) and by assessing striatal dopamine content. The degree of microglia activation in the SN was also immunohistochemistry assessed utilizing the marker OX-6 for activated microglia and CD-68 a marker for phagocytic microglia. Additionally we performed immunocytochemistry for MMP3 in the SN. Finally, we investigated whether a period of drug withdrawal for a further 7 days affected the neuroprotection produced by the PPAR\u03b3 agonists. KEY RESULTS: Both pioglitazone and GW855266X protected against 6-OHDA induced loss of dopaminergic neurons in the substantia nigra and depletion of striatal dopamine when administered orally twice daily for either 1) 7 day prior to and 7 days post lesioning or 2) for 7 days starting 2 days post lesioning when neurons will be severely traumatized. 6-OHDA lesioning was associated with an increase in microglia activation and in numbers of MMP-3 immunoreactive cells which was attenuated by pioglitazone and GW855266X. Neuroprotective effects were not replicated using the PPAR\u03b4 agonist GW610742X. Subsequent withdrawal of both pioglitazone and GW855266X, for a further 7 days negated any neuroprotective effect suggesting that long-term administration may be required to attenuate the inflammatory response. CONCLUSIONS AND IMPLICATIONS: For the first time a partial PPAR-\u03b3 agonist has been shown to be neuroprotectory when administered post lesioning in a parkinsonian model. Effects may be via the inhibition of microglial and MMP activation and support further research.", "electronicPublicationDate": "2012-04-11", "language": "eng", "dateOfCompletion": "2012-06-19", "fullTextUrlList": {"fullTextUrl": [{"url": "http://dx.doi.org/10.1016/j.jneuroim.2012.03.010", "documentStyle": "doi", "availability": "Subscription required", "availabilityCode": "S", "site": "DOI"}]}, "hasTextMinedTerms": "N", "dateOfRevision": "2012-11-15", "hasBook": "N", "journalInfo": {"printPublicationDate": "2012-05-01", "journal": {"medlineAbbreviation": "J Neuroimmunol", "isoabbreviation": "J. Neuroimmunol.", "title": "Journal of neuroimmunology", "issn": "0165-5728", "nlmid": "8109498", "essn": "1872-8421"}, "monthOfPublication": 5, "volume": "246", "yearOfPublication": 2012, "journalIssueId": 1925719, "issue": "1-2", "dateOfPublication": "2012 May"}}, "17167170": {"pubYear": "2007", "dateOfCreation": "2007-02-16", "pubModel": "Print-Electronic", "chemicalList": {"chemical": [{"registryNumber": "0", "name": "GW 501516"}, {"registryNumber": "0", "name": "Acetates"}, {"registryNumber": "0", "name": "Thiazoles"}, {"registryNumber": "0", "name": "Phenols"}, {"registryNumber": "0", "name": "Ligands"}, {"registryNumber": "0", "name": "Phenoxyacetates"}, {"registryNumber": "EC 3.4.22.-", "name": "Caspases"}, {"registryNumber": "0", "name": "Neuroprotective Agents"}, {"registryNumber": "0", "name": "PPAR delta"}, {"registryNumber": "0", "name": "4-(3-(2-propyl-3-hydroxy-4-acetyl)phenoxy)propyloxyphenoxy acetic acid"}]}, "authorString": "Iwashita A, Muramatsu Y, Yamazaki T, Muramoto M, Kita Y, Yamazaki S, Mihara K, Moriguchi A, Matsuoka N.", "affiliation": "Neuroscience Discovery Research, Pharmacology Research Laboratories, Astellas Pharma Inc., 21 Miyukigaoka, Tsukuba, Ibaraki 305-8585, Japan. akinori.iwashita@jp.astellas.com", "pubTypeList": {"pubType": ["Journal Article"]}, "hasPDF": "N", "id": "17167170", "inEPMC": "N", "authorList": {"author": [{"lastName": "Iwashita", "fullName": "Iwashita A", "firstName": "Akinori", "initials": "A"}, {"lastName": "Muramatsu", "fullName": "Muramatsu Y", "firstName": "Yuko", "initials": "Y"}, {"lastName": "Yamazaki", "fullName": "Yamazaki T", "firstName": "Takao", "initials": "T"}, {"lastName": "Muramoto", "fullName": "Muramoto M", "firstName": "Masakazu", "initials": "M"}, {"lastName": "Kita", "fullName": "Kita Y", "firstName": "Yasuhiro", "initials": "Y"}, {"lastName": "Yamazaki", "fullName": "Yamazaki S", "firstName": "Shunji", "initials": "S"}, {"lastName": "Mihara", "fullName": "Mihara K", "firstName": "Kayoko", "initials": "K"}, {"lastName": "Moriguchi", "fullName": "Moriguchi A", "firstName": "Akira", "initials": "A"}, {"lastName": "Matsuoka", "fullName": "Matsuoka N", "firstName": "Nobuya", "initials": "N"}]}, "title": "Neuroprotective efficacy of the peroxisome proliferator-activated receptor delta-selective agonists in vitro and in vivo.", "citedByCount": 52, "source": "MED", "pmid": "17167170", "hasLabsLinks": "Y", "subsetList": {"subset": [{"code": "IM", "name": "Index Medicus"}]}, "meshHeadingList": {"meshHeading": [{"descriptorName": "Brain", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "Y"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Cell Line, Tumor", "majorTopic_YN": "N"}, {"descriptorName": "Animals", "majorTopic_YN": "N"}, {"descriptorName": "Mice, Inbred C57BL", "majorTopic_YN": "N"}, {"descriptorName": "Humans", "majorTopic_YN": "N"}, {"descriptorName": "Mice", "majorTopic_YN": "N"}, {"descriptorName": "Rats", "majorTopic_YN": "N"}, {"descriptorName": "Rats, Wistar", "majorTopic_YN": "N"}, {"descriptorName": "Parkinson Disease", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "PC", "qualifierName": "prevention & control", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Brain Ischemia", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "PC", "qualifierName": "prevention & control", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Disease Models, Animal", "majorTopic_YN": "N"}, {"descriptorName": "Dopamine", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Acetates", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PK", "qualifierName": "pharmacokinetics", "majorTopic_YN": "N"}, {"abbreviation": "PD", "qualifierName": "pharmacology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Phenoxyacetates", "majorTopic_YN": "N"}, {"descriptorName": "Phenols", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PK", "qualifierName": "pharmacokinetics", "majorTopic_YN": "N"}, {"abbreviation": "PD", "qualifierName": "pharmacology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Thiazoles", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PK", "qualifierName": "pharmacokinetics", "majorTopic_YN": "N"}, {"abbreviation": "PD", "qualifierName": "pharmacology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Caspases", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "PPAR delta", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "AG", "qualifierName": "agonists", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Neuroprotective Agents", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PK", "qualifierName": "pharmacokinetics", "majorTopic_YN": "N"}, {"abbreviation": "PD", "qualifierName": "pharmacology", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Ligands", "majorTopic_YN": "N"}, {"descriptorName": "Cell Survival", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}]}}, {"descriptorName": "Substrate Specificity", "majorTopic_YN": "N"}, {"descriptorName": "Genes, Reporter", "majorTopic_YN": "N"}, {"descriptorName": "Male", "majorTopic_YN": "N"}]}, "inPMC": "N", "hasTMAccessionNumbers": "N", "hasReferences": "N", "firstPublicationDate": "2006-12-13", "doi": "10.1124/jpet.106.115758", "isOpenAccess": "N", "pageInfo": "1087-1096", "hasDbCrossReferences": "N", "abstractText": "Peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor superfamily and function as ligand-modulated transcription factors that regulate gene expression in many important biological processes. The PPARdelta subtype has the highest expression in the brain and is postulated to play a major role in neuronal cell function; however, the precise physiological roles of this receptor remain to be elucidated. Herein, we show that the high-affinity PPARdelta agonists L-165041 [4-[3-(4-acetyl-3-hydroxy-2-propylphenoxy)-propoxyl]phenoxy]-acetic acid] and GW501516 [2-methyl4-((4-methyl-2-(4-trifluoromethylphenyl)-1,3-triazol-5-yl)-methylsulfanyl)phenoxy acetic acid] protect against cytotoxin-induced SH-SY5Y cell injury in vitro and both ischemic brain injury and 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxicity in vivo. In the SH-SY5Y studies, treatment with L-165041 or GW501516 significantly and concentration-dependently attenuated cell death following thapsigargin, 1-methyl-4-phenylpyridinium, or staurosporine exposure, with the extent of damage correlated with the level of caspase-3 inhibition. In the transient (90 min) middle cerebral artery occlusion model of ischemic brain injury in rats, i.c.v. infusion of L-165041 or GW501516 significantly attenuated the ischemic brain damage measured 24 h after reperfusion. Moreover, the PPARdelta agonists also significantly attenuated MPTP-induced depletion of striatal dopamine and related metabolite contents in mouse brain. These results demonstrate that subtype-selective PPARdelta agonists possess antiapoptotic properties in vitro, which may underlie their potential neuroprotective potential in in vivo experimental models of cerebral ischemia and Parkinson's disease (PD). These findings suggest that PPARdelta agonists could be useful tools for understanding the role of PPARdelta in other neurodegenerative disorders, as well as attractive therapeutic candidates for stroke and neurodegenerative diseases such as PD.", "electronicPublicationDate": "2006-12-13", "language": "eng", "dateOfCompletion": "2007-04-09", "fullTextUrlList": {"fullTextUrl": [{"url": "http://dx.doi.org/10.1124/jpet.106.115758", "documentStyle": "doi", "availability": "Subscription required", "availabilityCode": "S", "site": "aspetjournals.org"}]}, "hasTextMinedTerms": "N", "dateOfRevision": "2012-11-15", "hasBook": "N", "journalInfo": {"printPublicationDate": "2007-03-01", "journal": {"medlineAbbreviation": "J Pharmacol Exp Ther", "isoabbreviation": "J. Pharmacol. Exp. Ther.", "title": "The Journal of pharmacology and experimental therapeutics", "issn": "0022-3565", "nlmid": "0376362", "essn": "1521-0103"}, "monthOfPublication": 3, "volume": "320", "yearOfPublication": 2007, "journalIssueId": 1378619, "issue": "3", "dateOfPublication": "2007 Mar"}}, "23500098": {"pubYear": "2013", "dateOfCreation": "2013-04-26", "pubModel": "Print-Electronic", "chemicalList": {"chemical": [{"registryNumber": "0", "name": "GW0742"}, {"registryNumber": "0", "name": "Thiophenes"}, {"registryNumber": "0", "name": "Thiazoles"}, {"registryNumber": "EC 1.14.16.2", "name": "Tyrosine 3-Monooxygenase"}, {"registryNumber": "0", "name": "Sulfones"}, {"registryNumber": "102-32-9", "name": "3,4-Dihydroxyphenylacetic Acid"}, {"registryNumber": "0", "name": "Macrophage-1 Antigen"}, {"registryNumber": "0", "name": "Glial Fibrillary Acidic Protein"}, {"registryNumber": "0", "name": "Neuroprotective Agents"}, {"registryNumber": "0", "name": "PPAR delta"}, {"registryNumber": "0", "name": "GSK0660"}, {"registryNumber": "VTD58H1Z2X", "name": "Dopamine"}]}, "authorString": "Martin HL, Mounsey RB, Sathe K, Mustafa S, Nelson MC, Evans RM, Teismann P.", "affiliation": "Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom.", "pubTypeList": {"pubType": ["Journal Article"]}, "grantsList": {"grant": [{"acronym": "HL", "orderIn": 0, "agency": "NHLBI NIH HHS", "grantId": "R01 HL105278"}, {"orderIn": 0, "agency": "Howard Hughes Medical Institute"}, {"acronym": "DK", "orderIn": 0, "agency": "NIDDK NIH HHS", "grantId": "R37 DK057978"}]}, "hasPDF": "Y", "id": "23500098", "inEPMC": "Y", "authorList": {"author": [{"affiliation": "Institute of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom.", "fullName": "Martin HL", "initials": "HL", "firstName": "H L", "lastName": "Martin"}, {"lastName": "Mounsey", "fullName": "Mounsey RB", "firstName": "R B", "initials": "RB"}, {"lastName": "Sathe", "fullName": "Sathe K", "firstName": "K", "initials": "K"}, {"lastName": "Mustafa", "fullName": "Mustafa S", "firstName": "S", "initials": "S"}, {"lastName": "Nelson", "fullName": "Nelson MC", "firstName": "M C", "initials": "MC"}, {"lastName": "Evans", "fullName": "Evans RM", "firstName": "R M", "initials": "RM"}, {"lastName": "Teismann", "fullName": "Teismann P", "firstName": "P", "initials": "P"}]}, "title": "A peroxisome proliferator-activated receptor-\u03b4 agonist provides neuroprotection in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine model of Parkinson's disease.", "hasSuppl": "N", "citedByCount": 9, "source": "MED", "pmid": "23500098", "hasLabsLinks": "Y", "subsetList": {"subset": [{"code": "IM", "name": "Index Medicus"}]}, "meshHeadingList": {"meshHeading": [{"descriptorName": "Cells, Cultured", "majorTopic_YN": "N"}, {"descriptorName": "Animals", "majorTopic_YN": "N"}, {"descriptorName": "Mice, Inbred C57BL", "majorTopic_YN": "N"}, {"descriptorName": "Mice, Transgenic", "majorTopic_YN": "N"}, {"descriptorName": "Humans", "majorTopic_YN": "N"}, {"descriptorName": "Mice", "majorTopic_YN": "N"}, {"descriptorName": "Rats", "majorTopic_YN": "N"}, {"descriptorName": "Parkinsonian Disorders", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Disease Models, Animal", "majorTopic_YN": "N"}, {"descriptorName": "Dopamine", "majorTopic_YN": "N"}, {"descriptorName": "3,4-Dihydroxyphenylacetic Acid", "majorTopic_YN": "N"}, {"descriptorName": "Sulfones", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PD", "qualifierName": "pharmacology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Thiazoles", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Thiophenes", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PD", "qualifierName": "pharmacology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Glial Fibrillary Acidic Protein", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Tyrosine 3-Monooxygenase", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Macrophage-1 Antigen", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "PPAR delta", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}, {"abbreviation": "AG", "qualifierName": "agonists", "majorTopic_YN": "N"}]}}, {"descriptorName": "Neuroprotective Agents", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Cell Count", "majorTopic_YN": "N"}, {"descriptorName": "Dose-Response Relationship, Drug", "majorTopic_YN": "N"}, {"descriptorName": "Female", "majorTopic_YN": "N"}, {"descriptorName": "Male", "majorTopic_YN": "N"}]}, "inPMC": "Y", "dbCrossReferenceList": {"dbName": ["UNIPROT"]}, "hasTMAccessionNumbers": "N", "hasReferences": "Y", "firstPublicationDate": "2013-03-07", "language": "eng", "doi": "10.1016/j.neuroscience.2013.02.058", "isOpenAccess": "Y", "pageInfo": "191-203", "pmcid": "PMC3661980", "hasDbCrossReferences": "Y", "abstractText": "Peroxisome proliferator-activated receptor (PPAR)-\u03b3 and PPAR\u03b1 have shown neuroprotective effects in models of Parkinson's disease (PD). The role of the third, more ubiquitous isoform PPAR\u03b4 has not been fully explored. This study investigated the role of PPAR\u03b4 in PD using 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) to model the dopaminergic neurodegeneration of PD. In vitro administration of the PPAR\u03b4 antagonist GSK0660 (1 \u03bcM) increased the detrimental effect of 1-methyl-4-phenylpyridinium iodide (MPP\u207a) on cell viability, which was reversed by co-treatment with agonist GW0742 (1 \u03bcM). GW0742 alone did not affect MPP\u207a toxicity. PPAR\u03b4 was expressed in the nucleus of dopaminergic neurons and in astrocytes. Striatal PPAR\u03b4 levels were increased (over two-fold) immediately after MPTP treatment (30 mg/kg for 5 consecutive days) compared to saline-treated mice. PPAR\u03b4 heterozygous mice were not protected against MPTP toxicity. Intra-striatal infusion of GW0742 (84 \u03bcg/day) reduced the MPTP-induced loss of dopaminergic neurons (5036\u00b1195) when compared to vehicle-infused mice (3953\u00b1460). These results indicate that agonism of PPAR\u03b4 provides protection against MPTP toxicity, in agreement with the effects of other PPAR agonists.", "electronicPublicationDate": "2013-03-07", "license": "cc by", "dateOfCompletion": "2013-11-13", "fullTextUrlList": {"fullTextUrl": [{"url": "http://europepmc.org/articles/PMC3661980", "documentStyle": "html", "availability": "Open access", "availabilityCode": "OA", "site": "Europe_PMC"}, {"url": "http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=EBI&pubmedid=23500098", "documentStyle": "html", "availability": "Free", "availabilityCode": "F", "site": "PubMedCentral"}, {"url": "http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=EBI&pubmedid=23500098&action=stream&blobtype=pdf", "documentStyle": "pdf", "availability": "Free", "availabilityCode": "F", "site": "PubMedCentral"}, {"url": "http://dx.doi.org/10.1016/j.neuroscience.2013.02.058", "documentStyle": "doi", "availability": "Subscription required", "availabilityCode": "S", "site": "DOI"}]}, "hasTextMinedTerms": "Y", "dateOfRevision": "2014-11-24", "hasBook": "N", "journalInfo": {"printPublicationDate": "2013-06-01", "journal": {"medlineAbbreviation": "Neuroscience", "isoabbreviation": "Neuroscience", "title": "Neuroscience", "issn": "0306-4522", "nlmid": "7605074", "essn": "1873-7544"}, "monthOfPublication": 6, "volume": "240", "yearOfPublication": 2013, "journalIssueId": 2033348, "dateOfPublication": "2013 Jun"}}, "21685825": {"pubYear": "2012", "dateOfCreation": "2012-01-05", "pubModel": "Print", "chemicalList": {"chemical": [{"registryNumber": "0", "name": "GW0742"}, {"registryNumber": "0", "name": "Thiazoles"}, {"registryNumber": "0", "name": "Protein Isoforms"}, {"registryNumber": "0", "name": "Neuroprotective Agents"}, {"registryNumber": "0", "name": "PPAR delta"}]}, "authorString": "Esposito E, Paterniti I, Meli R, Bramanti P, Cuzzocrea S.", "affiliation": "Department of Clinical and Experimental Medicine and Pharmacology, School of Medicine, University of Messina, Italy.", "pubTypeList": {"pubType": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "hasPDF": "N", "id": "21685825", "inEPMC": "N", "authorList": {"author": [{"lastName": "Esposito", "fullName": "Esposito E", "firstName": "Emanuela", "initials": "E"}, {"lastName": "Paterniti", "fullName": "Paterniti I", "firstName": "Irene", "initials": "I"}, {"lastName": "Meli", "fullName": "Meli R", "authorId": {"type": "ORCID", "value": "0000-0002-6246-6813"}, "firstName": "Rosaria", "initials": "R"}, {"lastName": "Bramanti", "fullName": "Bramanti P", "firstName": "Placido", "initials": "P"}, {"lastName": "Cuzzocrea", "fullName": "Cuzzocrea S", "firstName": "Salvatore", "initials": "S"}]}, "title": "GW0742, a high-affinity PPAR-\u03b4 agonist, mediates protection in an organotypic model of spinal cord damage.", "citedByCount": 4, "source": "MED", "pmid": "21685825", "hasLabsLinks": "N", "subsetList": {"subset": [{"code": "IM", "name": "Index Medicus"}]}, "authorIdList": {"authorId": [{"type": "ORCID", "value": "0000-0002-6246-6813"}]}, "meshHeadingList": {"meshHeading": [{"descriptorName": "Spinal Cord", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}, {"abbreviation": "PP", "qualifierName": "physiopathology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Animals", "majorTopic_YN": "N"}, {"descriptorName": "Mice", "majorTopic_YN": "N"}, {"descriptorName": "Spinal Cord Injuries", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "PP", "qualifierName": "physiopathology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Nerve Degeneration", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DT", "qualifierName": "drug therapy", "majorTopic_YN": "Y"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "PP", "qualifierName": "physiopathology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Thiazoles", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PD", "qualifierName": "pharmacology", "majorTopic_YN": "Y"}, {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "N"}]}}, {"descriptorName": "Protein Isoforms", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PH", "qualifierName": "physiology", "majorTopic_YN": "N"}, {"abbreviation": "AG", "qualifierName": "agonists", "majorTopic_YN": "N"}]}}, {"descriptorName": "PPAR delta", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PH", "qualifierName": "physiology", "majorTopic_YN": "N"}, {"abbreviation": "AG", "qualifierName": "agonists", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Neuroprotective Agents", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PD", "qualifierName": "pharmacology", "majorTopic_YN": "Y"}, {"abbreviation": "TU", "qualifierName": "therapeutic use", "majorTopic_YN": "N"}]}}, {"descriptorName": "Organ Culture Techniques", "majorTopic_YN": "N"}, {"descriptorName": "Models, Biological", "majorTopic_YN": "N"}]}, "inPMC": "N", "hasTMAccessionNumbers": "N", "hasReferences": "Y", "firstPublicationDate": "2012-01-01", "doi": "10.1097/brs.0b013e3182276d88", "isOpenAccess": "N", "pageInfo": "E73-8", "hasDbCrossReferences": "N", "abstractText": " STUDY DESIGN: Experimental study of spinal cord injury (SCI) using an organotypic slice culture. OBJECTIVE: To clarify the protective mechanism of PPAR-\u03b4 agonist GW0742 in the injured spinal cord using an in vitro model. SUMMARY OF BACKGROUND DATA: In vivo data suggest that ligands of the \u03b4 isoform have activity in a number of disease models that are partly driven by the inflammatory response. Moreover, reports from in vivo studies using models of ischemia reperfusion and Parkinson disease also have shown neuroprotection conferred by PPAR-\u03b4. The biological role and function of PPAR-\u03b4 remains relatively unclear. METHODS: Spinal cord from 6-week-old mice was cut into transverse slices of 400-\u03bcm thickness to generate the organotypic slice cultures. The slices were injured using a weight dropped onto the center of the slice. PPAR-\u03b4 agonist was applied at 10 \u03bcM at 1 hour before injury. RESULTS: Our study shows that GW0742 incubation (10 \u03bcM) at 1 hour before transverse lesion significantly reduced (1) p38 mitogen-activated protein kinase (MAPK), (2) c-Jun N-terminal kinase (JNK/SAP kinase), (3) NF-\u03baB activation, (4) loss of neurotrophic factors (BDNF, GDNF), (5) COX-2 expression, and (6) cell death. CONCLUSION: GW0742 reduces the cellular and molecular changes occurring in SCI by targeting different downstream pathways modulating PPAR-\u03b4 receptors.", "language": "eng", "dateOfCompletion": "2012-09-24", "fullTextUrlList": {"fullTextUrl": [{"url": "http://dx.doi.org/10.1097/BRS.0b013e3182276d88", "documentStyle": "doi", "availability": "Subscription required", "availabilityCode": "S", "site": "DOI"}]}, "hasTextMinedTerms": "N", "hasBook": "N", "journalInfo": {"printPublicationDate": "2012-01-01", "journal": {"medlineAbbreviation": "Spine (Phila Pa 1976)", "isoabbreviation": "Spine", "title": "Spine", "issn": "0362-2436", "nlmid": "7610646", "essn": "1528-1159"}, "monthOfPublication": 1, "volume": "37", "yearOfPublication": 2012, "journalIssueId": 1893457, "issue": "2", "dateOfPublication": "2012 Jan"}}, "24635117": {"pubYear": "2014", "dateOfCreation": "2014-05-09", "pubModel": "Print", "chemicalList": {"chemical": [{"registryNumber": "0", "name": "GW0742"}, {"registryNumber": "0", "name": "Thiazoles"}, {"registryNumber": "0", "name": "Neuroprotective Agents"}, {"registryNumber": "0", "name": "PPAR delta"}, {"registryNumber": "0", "name": "PPAR-beta"}]}, "authorString": "Das NR, Gangwal RP, Damre MV, Sangamwar AT, Sharma SS.", "pubTypeList": {"pubType": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "hasPDF": "N", "id": "24635117", "inEPMC": "N", "authorList": {"author": [{"lastName": "Das", "fullName": "Das NR", "firstName": "Nihar R", "initials": "NR"}, {"lastName": "Gangwal", "fullName": "Gangwal RP", "firstName": "Rahul P", "initials": "RP"}, {"lastName": "Damre", "fullName": "Damre MV", "authorId": {"type": "ORCID", "value": "0000-0002-4371-3815"}, "firstName": "Mangesh V", "initials": "MV"}, {"lastName": "Sangamwar", "fullName": "Sangamwar AT", "firstName": "Abhay T", "initials": "AT"}, {"affiliation": "Department of Pharmacology and Toxicology, National Institute of Pharmaceutical Education and Research (NIPER), Sector-67, SAS Nagar, Punjab-160062, India. sssharma@niper.ac.in.", "fullName": "Sharma SS", "initials": "SS", "firstName": "Shyam S", "lastName": "Sharma"}]}, "title": "A PPAR-\u03b2/\u03b4 agonist is neuroprotective and decreases cognitive impairment in a rodent model of Parkinson's disease.", "citedByCount": 3, "source": "MED", "pmid": "24635117", "hasLabsLinks": "N", "subsetList": {"subset": [{"code": "IM", "name": "Index Medicus"}]}, "authorIdList": {"authorId": [{"type": "ORCID", "value": "0000-0002-4371-3815"}]}, "meshHeadingList": {"meshHeading": [{"descriptorName": "Brain", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Neurons", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Animals", "majorTopic_YN": "N"}, {"descriptorName": "Rats", "majorTopic_YN": "N"}, {"descriptorName": "Rats, Sprague-Dawley", "majorTopic_YN": "N"}, {"descriptorName": "Parkinsonian Disorders", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Disease Models, Animal", "majorTopic_YN": "N"}, {"descriptorName": "Thiazoles", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PK", "qualifierName": "pharmacokinetics", "majorTopic_YN": "N"}, {"abbreviation": "PD", "qualifierName": "pharmacology", "majorTopic_YN": "Y"}]}}, {"descriptorName": "PPAR-beta", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AG", "qualifierName": "agonists", "majorTopic_YN": "N"}]}}, {"descriptorName": "PPAR delta", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "AG", "qualifierName": "agonists", "majorTopic_YN": "N"}]}}, {"descriptorName": "Neuroprotective Agents", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PK", "qualifierName": "pharmacokinetics", "majorTopic_YN": "N"}, {"abbreviation": "PD", "qualifierName": "pharmacology", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Blotting, Western", "majorTopic_YN": "N"}, {"descriptorName": "In Situ Nick-End Labeling", "majorTopic_YN": "N"}, {"descriptorName": "Cognition", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Maze Learning", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}]}}, {"descriptorName": "DNA Fragmentation", "majorTopic_YN": "N"}, {"descriptorName": "Male", "majorTopic_YN": "N"}]}, "inPMC": "N", "hasTMAccessionNumbers": "N", "hasReferences": "N", "firstPublicationDate": "2014-05-01", "doi": "10.2174/1567202611666140318114037", "isOpenAccess": "N", "pageInfo": "114-124", "hasDbCrossReferences": "N", "abstractText": "Parkinson's disease (PD) is associated with higher risk of cognitive impairment that may lead to memory loss, confusion, and decreased attention span. In this study, we have investigated the effect of GW0742, a PPAR-\u03b2/\u03b4 agonist in rat model of cognitive impairment associated with PD. Bilateral intranigral administration of 1-methyl-4-phenyl-1,2,3,6- tetrahydropyridine (MPTP) (100 \u00b5g/1 \u00b5l/side) produced significant cognitive dysfunctions. PPAR-\u03b2/\u03b4 agonist GW0742 at a dose of 30 and 100 \u00b5g/kg showed significant improvement in cognitive impairments caused by MPTP in rat model of PD as evident from passive avoidance and Morris water maze test. MPTP-induced massive oxidative damage and DNA fragmentation was ameliorated by GW0742 treatment as observed after MDA and GSH estimation and TUNEL assay. Tyrosine hydroxylase positive neurons were decreased by 25% of normal control in MPTP group and GW0742 treatment restored tyrosine hydroxylase levels showing neuroprotective nature. Further, we performed physiologically based pharmacokinetic (PBPK) modeling study using GastroPlus to characterize the kinetics of GW0742 in the brain. The predicted amounts of GW0742 in brain suggest that it has the ability to cross the blood brain barrier. This study implicates the involvement of PPAR-\u03b2/\u03b4 in PD induced cognitive impairment.", "language": "eng", "dateOfCompletion": "2014-12-31", "fullTextUrlList": {"fullTextUrl": [{"url": "http://dx.doi.org/10.2174/1567202611666140318114037", "documentStyle": "doi", "availability": "Subscription required", "availabilityCode": "S", "site": "DOI"}]}, "hasTextMinedTerms": "N", "hasBook": "N", "journalInfo": {"printPublicationDate": "2014-05-01", "journal": {"medlineAbbreviation": "Curr Neurovasc Res", "isoabbreviation": "Curr Neurovasc Res", "title": "Current neurovascular research", "issn": "1567-2026", "nlmid": "101208439", "essn": "1875-5739"}, "monthOfPublication": 5, "volume": "11", "yearOfPublication": 2014, "journalIssueId": 2158517, "issue": "2", "dateOfPublication": "2014 May"}}, "22135673": {"pubYear": "2011", "dateOfCreation": "2011-12-02", "pubModel": "Print-Electronic", "authorString": "Schnegg CI, Robbins ME.", "affiliation": "Department of Cancer Biology, Comprehensive Cancer Center, Wake Forest School of Medicine, Winston-Salem, NC 27157, USA.", "pubTypeList": {"pubType": ["Journal Article"]}, "id": "22135673", "inEPMC": "Y", "authorList": {"author": [{"lastName": "Schnegg", "fullName": "Schnegg CI", "firstName": "Caroline I", "initials": "CI"}, {"lastName": "Robbins", "fullName": "Robbins ME", "firstName": "Mike E", "initials": "ME"}]}, "title": "Neuroprotective Mechanisms of PPAR\u03b4: Modulation of Oxidative Stress and Inflammatory Processes.", "hasSuppl": "N", "citedByCount": 14, "source": "MED", "pmid": "22135673", "hasLabsLinks": "N", "hasTextMinedTerms": "Y", "hasPDF": "Y", "inPMC": "Y", "hasTMAccessionNumbers": "N", "hasReferences": "Y", "firstPublicationDate": "2011-10-29", "doi": "10.1155/2011/373560", "isOpenAccess": "Y", "pageInfo": "373560", "pmcid": "PMC3205692", "hasDbCrossReferences": "N", "abstractText": "Peroxisome proliferator-activated receptors (PPAR\u03b1, \u03b4, and \u03b3) are ligand-activated transcription factors that regulate a wide range of cellular processes, including inflammation, proliferation, differentiation, metabolism, and energy homeostasis. All three PPAR subtypes have been identified in the central nervous system (CNS) of rodents. While PPAR\u03b1 and PPAR\u03b3 are expressed in more restricted areas of the CNS, PPAR\u03b4 is ubiquitously expressed and is the predominant subtype. Although data regarding PPAR\u03b4 are limited, studies have demonstrated that administration of PPAR\u03b4 agonists confers neuroprotection following various acute and chronic injuries to the CNS, such as stroke, multiple sclerosis, and Alzheimer's disease. The antioxidant and anti-inflammatory properties of PPAR\u03b4 agonists are thought to underly their neuroprotective efficacy. This review will focus on the putative neuroprotective benefits of therapeutically targeting PPAR\u03b4 in the CNS, and specifically, highlight the antioxidant and anti-inflammatory functions of PPAR\u03b4 agonists.", "electronicPublicationDate": "2011-10-29", "language": "eng", "dateOfCompletion": "2012-08-23", "fullTextUrlList": {"fullTextUrl": [{"url": "http://europepmc.org/articles/PMC3205692?pdf=render", "documentStyle": "pdf", "availability": "Open access", "availabilityCode": "OA", "site": "Europe_PMC"}, {"url": "http://europepmc.org/articles/PMC3205692", "documentStyle": "html", "availability": "Open access", "availabilityCode": "OA", "site": "Europe_PMC"}, {"url": "http://www.hindawi.com/GetPDF.aspx?doi=10.1155/2011/373560", "documentStyle": "pdf", "availability": "Open access", "availabilityCode": "OA", "site": "hindawi.com"}, {"url": "http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=EBI&pubmedid=22135673&action=stream&blobtype=pdf", "documentStyle": "pdf", "availability": "Free", "availabilityCode": "F", "site": "PubMedCentral"}, {"url": "http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=EBI&pubmedid=22135673", "documentStyle": "html", "availability": "Free", "availabilityCode": "F", "site": "PubMedCentral"}, {"url": "http://dx.doi.org/10.1155/2011/373560", "documentStyle": "doi", "availability": "Subscription required", "availabilityCode": "S", "site": "DOI"}]}, "hasBook": "N", "journalInfo": {"printPublicationDate": "2011-01-01", "journal": {"medlineAbbreviation": "PPAR Res", "isoabbreviation": "PPAR Res", "title": "PPAR research", "issn": "1687-4757", "nlmid": "101269101", "essn": "1687-4765"}, "monthOfPublication": 0, "volume": "2011", "yearOfPublication": 2011, "journalIssueId": 1849194, "dateOfPublication": "2011 "}}, "26028469": {"pubYear": "2015", "dateOfCreation": "2015-06-26", "pubModel": "Print-Electronic", "chemicalList": {"chemical": [{"registryNumber": "EC 1.14.16.2", "name": "Tyrosine 3-Monooxygenase"}, {"registryNumber": "102-32-9", "name": "3,4-Dihydroxyphenylacetic Acid"}, {"registryNumber": "0", "name": "PPAR gamma"}, {"registryNumber": "0", "name": "PPAR delta"}, {"registryNumber": "VTD58H1Z2X", "name": "Dopamine"}]}, "authorString": "Mounsey RB, Martin HL, Nelson MC, Evans RM, Teismann P.", "affiliation": "School of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom.", "pubTypeList": {"pubType": ["Journal Article", "Research Support, Non-U.S. Gov't", "Research Support, N.I.H., Extramural"]}, "grantsList": {"grant": [{"acronym": "DK", "orderIn": 0, "agency": "NIDDK NIH HHS", "grantId": "DK057978"}, {"acronym": "DK", "orderIn": 0, "agency": "NIDDK NIH HHS", "grantId": "R37 DK057978"}, {"orderIn": 0, "agency": "Howard Hughes Medical Institute"}, {"orderIn": 0, "agency": "Biotechnology and Biological Sciences Research Council"}, {"orderIn": 0, "agency": "Wellcome Trust", "grantId": "WT080782MF"}]}, "hasPDF": "Y", "id": "26028469", "inEPMC": "Y", "authorList": {"author": [{"affiliation": "School of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom.", "fullName": "Mounsey RB", "initials": "RB", "firstName": "R B", "lastName": "Mounsey"}, {"affiliation": "School of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom; Institute of Molecular Medicine, University of Leeds, Leeds, United Kingdom.", "fullName": "Martin HL", "initials": "HL", "firstName": "H L", "lastName": "Martin"}, {"affiliation": "Gene Expression Laboratory, Salk Institute, La Jolla, CA, USA.", "fullName": "Nelson MC", "initials": "MC", "firstName": "M C", "lastName": "Nelson"}, {"affiliation": "Gene Expression Laboratory, Salk Institute, La Jolla, CA, USA.", "fullName": "Evans RM", "initials": "RM", "firstName": "R M", "lastName": "Evans"}, {"affiliation": "School of Medical Sciences, University of Aberdeen, Aberdeen, United Kingdom. Electronic address: p.teismann@abdn.ac.uk.", "fullName": "Teismann P", "initials": "P", "firstName": "P", "lastName": "Teismann"}]}, "title": "The effect of neuronal conditional knock-out of peroxisome proliferator-activated receptors in the MPTP mouse model of Parkinson's disease.", "hasSuppl": "N", "citedByCount": 0, "source": "MED", "pmid": "26028469", "hasLabsLinks": "Y", "subsetList": {"subset": [{"code": "IM", "name": "Index Medicus"}]}, "meshHeadingList": {"meshHeading": [{"descriptorName": "Brain", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Neuroglia", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Animals", "majorTopic_YN": "N"}, {"descriptorName": "Mice, Inbred C57BL", "majorTopic_YN": "N"}, {"descriptorName": "Mice, Knockout", "majorTopic_YN": "N"}, {"descriptorName": "MPTP Poisoning", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Dopamine", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "3,4-Dihydroxyphenylacetic Acid", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Tyrosine 3-Monooxygenase", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "PPAR delta", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}, {"descriptorName": "PPAR gamma", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "GE", "qualifierName": "genetics", "majorTopic_YN": "N"}, {"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Fluorescent Antibody Technique", "majorTopic_YN": "N"}, {"descriptorName": "Chromatography, High Pressure Liquid", "majorTopic_YN": "N"}, {"descriptorName": "Immunohistochemistry", "majorTopic_YN": "N"}, {"descriptorName": "Male", "majorTopic_YN": "N"}, {"descriptorName": "Dopaminergic Neurons", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}]}}]}, "inPMC": "N", "dbCrossReferenceList": {"dbName": ["UNIPROT"]}, "hasTMAccessionNumbers": "N", "hasReferences": "Y", "firstPublicationDate": "2015-05-29", "language": "eng", "doi": "10.1016/j.neuroscience.2015.05.048", "isOpenAccess": "Y", "pageInfo": "576-584", "pmcid": "PMC4512257", "hasDbCrossReferences": "Y", "keywordList": {"keyword": ["MPTP", "Neurodegeneration", "Peroxisome proliferator-activated receptor", "Parkinson\u2019s Disease"]}, "abstractText": "Activation of peroxisome proliferator-activated receptors (PPARs), namely PPAR\u03b3 and PPAR\u03b4, has been shown to provide neuroprotection in a number of neurodegenerative disorders, such as Alzheimer's and Parkinson's disease (PD). The observed neuroprotective effects in experimental models of PD have been linked to anti-oxidant and anti-inflammatory actions. This study aimed to analyze the full influence of these receptors in neuroprotection by generating a nerve cell-specific conditional knock-out of these receptors and subjecting these genetically modified mice to the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) neurotoxin to model dopaminergic degeneration. Mice null for both receptors show the lowest levels of tyrosine hydroxylase (TH)-positive cell bodies following MPTP administration. Presence of one or both these receptors show a trend toward protection against this degeneration, as higher dopaminergic cell immunoreactivity and striatal monoamine levels are evident. These data supplement recent studies that have elected to use agonists of the receptors to regulate immune responses. The results place further importance on the activation of PPARs and the neuroprotective roles these have in inflammatory processes linked to neurodegenerative processes.", "electronicPublicationDate": "2015-05-29", "license": "cc by", "dateOfCompletion": "2016-03-29", "fullTextUrlList": {"fullTextUrl": [{"url": "http://europepmc.org/articles/PMC4512257?pdf=render", "documentStyle": "pdf", "availability": "Open access", "availabilityCode": "OA", "site": "Europe_PMC"}, {"url": "http://europepmc.org/articles/PMC4512257", "documentStyle": "html", "availability": "Open access", "availabilityCode": "OA", "site": "Europe_PMC"}, {"url": "http://dx.doi.org/10.1016/j.neuroscience.2015.05.048", "documentStyle": "doi", "availability": "Subscription required", "availabilityCode": "S", "site": "DOI"}]}, "hasTextMinedTerms": "Y", "dateOfRevision": "2015-08-19", "hasBook": "N", "journalInfo": {"printPublicationDate": "2015-08-01", "journal": {"medlineAbbreviation": "Neuroscience", "isoabbreviation": "Neuroscience", "title": "Neuroscience", "issn": "0306-4522", "nlmid": "7605074", "essn": "1873-7544"}, "monthOfPublication": 8, "volume": "300", "yearOfPublication": 2015, "journalIssueId": 2298050, "dateOfPublication": "2015 Aug"}}}, "PUM1": {"18776931": {"pubYear": "2008", "dateOfCreation": "2008-09-08", "pubModel": "Electronic", "chemicalList": {"chemical": [{"registryNumber": "0", "name": "PUM1 protein, human"}, {"registryNumber": "0", "name": "PUM2 protein, human"}, {"registryNumber": "0", "name": "RNA, Messenger"}, {"registryNumber": "0", "name": "DNA Primers"}, {"registryNumber": "0", "name": "RNA-Binding Proteins"}, {"registryNumber": "0", "name": "MicroRNAs"}]}, "authorString": "Galgano A, Forrer M, Jaskiewicz L, Kanitz A, Zavolan M, Gerber AP.", "affiliation": "Institute of Pharmaceutical Sciences, ETH Zurich, Zurich, Switzerland.", "pubTypeList": {"pubType": ["Journal Article", "Research Support, Non-U.S. Gov't", "Comparative Study"]}, "hasPDF": "Y", "id": "18776931", "inEPMC": "Y", "authorList": {"author": [{"lastName": "Galgano", "fullName": "Galgano A", "firstName": "Alessia", "initials": "A"}, {"lastName": "Forrer", "fullName": "Forrer M", "firstName": "Michael", "initials": "M"}, {"lastName": "Jaskiewicz", "fullName": "Jaskiewicz L", "firstName": "Lukasz", "initials": "L"}, {"lastName": "Kanitz", "fullName": "Kanitz A", "firstName": "Alexander", "initials": "A"}, {"lastName": "Zavolan", "fullName": "Zavolan M", "firstName": "Mihaela", "initials": "M"}, {"lastName": "Gerber", "fullName": "Gerber AP", "firstName": "Andr\u00e9 P", "initials": "AP"}]}, "title": "Comparative analysis of mRNA targets for human PUF-family proteins suggests extensive interaction with the miRNA regulatory system.", "hasSuppl": "Y", "citedByCount": 110, "source": "MED", "pmid": "18776931", "hasLabsLinks": "N", "subsetList": {"subset": [{"code": "IM", "name": "Index Medicus"}]}, "meshHeadingList": {"meshHeading": [{"descriptorName": "Hela Cells", "majorTopic_YN": "N"}, {"descriptorName": "Animals", "majorTopic_YN": "N"}, {"descriptorName": "Humans", "majorTopic_YN": "N"}, {"descriptorName": "Drosophila melanogaster", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "RNA-Binding Proteins", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}, {"abbreviation": "CH", "qualifierName": "chemistry", "majorTopic_YN": "Y"}]}}, {"descriptorName": "MicroRNAs", "majorTopic_YN": "Y"}, {"descriptorName": "RNA, Messenger", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "Y"}]}}, {"descriptorName": "DNA Primers", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "CH", "qualifierName": "chemistry", "majorTopic_YN": "N"}]}}, {"descriptorName": "Gene Expression Regulation", "majorTopic_YN": "Y"}, {"descriptorName": "Binding Sites", "majorTopic_YN": "N"}, {"descriptorName": "Amino Acid Motifs", "majorTopic_YN": "N"}, {"descriptorName": "Protein Binding", "majorTopic_YN": "N"}, {"descriptorName": "Multigene Family", "majorTopic_YN": "N"}]}, "inPMC": "Y", "dbCrossReferenceList": {"dbName": ["UNIPROT", "ARXPR"]}, "hasTMAccessionNumbers": "N", "hasReferences": "Y", "firstPublicationDate": "2008-09-08", "doi": "10.1371/journal.pone.0003164", "isOpenAccess": "Y", "pageInfo": "e3164", "pmcid": "PMC2522278", "hasDbCrossReferences": "Y", "abstractText": "Genome-wide identification of mRNAs regulated by RNA-binding proteins is crucial to uncover post-transcriptional gene regulatory systems. The conserved PUF family RNA-binding proteins repress gene expression post-transcriptionally by binding to sequence elements in 3'-UTRs of mRNAs. Despite their well-studied implications for development and neurogenesis in metazoa, the mammalian PUF family members are only poorly characterized and mRNA targets are largely unknown. We have systematically identified the mRNAs associated with the two human PUF proteins, PUM1 and PUM2, by the recovery of endogenously formed ribonucleoprotein complexes and the analysis of associated RNAs with DNA microarrays. A largely overlapping set comprised of hundreds of mRNAs were reproducibly associated with the paralogous PUM proteins, many of them encoding functionally related proteins. A characteristic PUF-binding motif was highly enriched among PUM bound messages and validated with RNA pull-down experiments. Moreover, PUF motifs as well as surrounding sequences exhibit higher conservation in PUM bound messages as opposed to transcripts that were not found to be associated, suggesting that PUM function may be modulated by other factors that bind conserved elements. Strikingly, we found that PUF motifs are enriched around predicted miRNA binding sites and that high-confidence miRNA binding sites are significantly enriched in the 3'-UTRs of experimentally determined PUM1 and PUM2 targets, strongly suggesting an interaction of human PUM proteins with the miRNA regulatory system. Our work suggests extensive connections between the RBP and miRNA post-transcriptional regulatory systems and provides a framework for deciphering the molecular mechanism by which PUF proteins regulate their target mRNAs.", "electronicPublicationDate": "2008-09-08", "language": "eng", "dateOfCompletion": "2008-11-25", "fullTextUrlList": {"fullTextUrl": [{"url": "http://europepmc.org/articles/PMC2522278?pdf=render", "documentStyle": "pdf", "availability": "Open access", "availabilityCode": "OA", "site": "Europe_PMC"}, {"url": "http://europepmc.org/articles/PMC2522278", "documentStyle": "html", "availability": "Open access", "availabilityCode": "OA", "site": "Europe_PMC"}, {"url": "http://www.pubmedcentral.nih.gov/picrender.fcgi?tool=EBI&pubmedid=18776931&action=stream&blobtype=pdf", "documentStyle": "pdf", "availability": "Free", "availabilityCode": "F", "site": "PubMedCentral"}, {"url": "http://www.pubmedcentral.nih.gov/articlerender.fcgi?tool=EBI&pubmedid=18776931", "documentStyle": "html", "availability": "Free", "availabilityCode": "F", "site": "PubMedCentral"}, {"url": "http://dx.doi.org/10.1371/journal.pone.0003164", "documentStyle": "doi", "availability": "Subscription required", "availabilityCode": "S", "site": "DOI"}]}, "hasTextMinedTerms": "Y", "dateOfRevision": "2009-11-18", "hasBook": "N", "journalInfo": {"printPublicationDate": "2008-01-01", "journal": {"title": "PloS one", "medlineAbbreviation": "PLoS One", "isoabbreviation": "PLoS ONE", "nlmid": "101285081", "essn": "1932-6203"}, "monthOfPublication": 0, "volume": "3", "yearOfPublication": 2008, "journalIssueId": 1553793, "issue": "9", "dateOfPublication": "2008 "}}}, "NTM": {"10739641": {"pubYear": "2000", "dateOfCreation": "2000-05-23", "pubModel": "Print", "chemicalList": {"chemical": [{"registryNumber": "51-61-6", "name": "Dopamine"}, {"registryNumber": "300-62-9", "name": "Amphetamine"}, {"registryNumber": "EC 1.14.16.2", "name": "Tyrosine 3-Monooxygenase"}, {"registryNumber": "7447-41-8", "name": "Lithium Chloride"}, {"registryNumber": "1199-18-4", "name": "Oxidopamine"}]}, "authorString": "Baker KA, Hong M, Sadi D, Mendez I.", "affiliation": "Department of Anatomy and Neurobiology, Dalhousie University, Halifax, Nova Scotia, B3H 4H7, Canada.", "pubTypeList": {"pubType": ["Journal Article", "Research Support, Non-U.S. Gov't"]}, "hasPDF": "N", "id": "10739641", "inEPMC": "N", "authorList": {"author": [{"lastName": "Baker", "fullName": "Baker KA", "initials": "KA"}, {"lastName": "Hong", "fullName": "Hong M", "initials": "M"}, {"lastName": "Sadi", "fullName": "Sadi D", "initials": "D"}, {"lastName": "Mendez", "fullName": "Mendez I", "initials": "I"}]}, "title": "Intrastriatal and intranigral grafting of hNT neurons in the 6-OHDA rat model of Parkinson's disease.", "citedByCount": 33, "source": "MED", "pmid": "10739641", "hasLabsLinks": "N", "subsetList": {"subset": [{"code": "IM", "name": "Index Medicus"}]}, "meshHeadingList": {"meshHeading": [{"descriptorName": "Substantia Nigra", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "EN", "qualifierName": "enzymology", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Corpus Striatum", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "EN", "qualifierName": "enzymology", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Neurons", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "CY", "qualifierName": "cytology", "majorTopic_YN": "N"}, {"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}, {"abbreviation": "EN", "qualifierName": "enzymology", "majorTopic_YN": "N"}, {"abbreviation": "TR", "qualifierName": "transplantation", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Cell Line", "majorTopic_YN": "N"}, {"descriptorName": "Stem Cells", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}, {"abbreviation": "EN", "qualifierName": "enzymology", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Animals", "majorTopic_YN": "N"}, {"descriptorName": "Humans", "majorTopic_YN": "N"}, {"descriptorName": "Rats", "majorTopic_YN": "N"}, {"descriptorName": "Rats, Wistar", "majorTopic_YN": "N"}, {"descriptorName": "Teratocarcinoma", "majorTopic_YN": "N"}, {"descriptorName": "Parkinson Disease, Secondary", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "CI", "qualifierName": "chemically induced", "majorTopic_YN": "N"}, {"abbreviation": "PA", "qualifierName": "pathology", "majorTopic_YN": "N"}, {"abbreviation": "TH", "qualifierName": "therapy", "majorTopic_YN": "Y"}]}}, {"descriptorName": "Disease Models, Animal", "majorTopic_YN": "N"}, {"descriptorName": "Lithium Chloride", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PD", "qualifierName": "pharmacology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Dopamine", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "ME", "qualifierName": "metabolism", "majorTopic_YN": "N"}]}}, {"descriptorName": "Oxidopamine", "majorTopic_YN": "N"}, {"descriptorName": "Amphetamine", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "PD", "qualifierName": "pharmacology", "majorTopic_YN": "N"}]}}, {"descriptorName": "Tyrosine 3-Monooxygenase", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "BI", "qualifierName": "biosynthesis", "majorTopic_YN": "N"}]}}, {"descriptorName": "Stem Cell Transplantation", "majorTopic_YN": "Y"}, {"descriptorName": "Transplantation, Heterologous", "majorTopic_YN": "N"}, {"descriptorName": "Cell Count", "majorTopic_YN": "N"}, {"descriptorName": "Motor Activity", "majorTopic_YN": "N", "meshQualifierList": {"meshQualifier": [{"abbreviation": "DE", "qualifierName": "drug effects", "majorTopic_YN": "N"}]}}, {"descriptorName": "Graft Survival", "majorTopic_YN": "N"}, {"descriptorName": "Female", "majorTopic_YN": "N"}]}, "inPMC": "N", "hasTMAccessionNumbers": "N", "hasReferences": "Y", "firstPublicationDate": "2000-04-01", "doi": "10.1006/exnr.1999.7337", "isOpenAccess": "N", "pageInfo": "350-360", "hasDbCrossReferences": "N", "abstractText": "The clinical findings on neural transplantation for Parkinson's disease (PD) reported thus far are promising but many issues must be addressed before neural transplantation can be considered a routine therapeutic option for PD. The future of neural transplantation for the treatment of neurological disorders may rest in the discovery of a suitable alternative cell type for fetal tissue. One such alternative may be neurons derived from a human teratocarcinoma (hNT). hNT neurons have been shown to survive and integrate within the host brain following transplantation and provide functional recovery in animal models of stroke and Huntington's disease. In this study, we describe the transplantation of hNT neurons in the substantia nigra (SN) and striatum of the rat model for PD. Twenty-seven rats were grafted with one of three hNT neuronal products; hNT neurons, hNT-DA neurons, or lithium chloride (LiCl) pretreated hNT-DA neurons. Robust hNT grafts could be seen with anti-neural cell adhesion molecule and anti-neuron-specific enolase immunostaining. Immunostaining for tyrosine hydroxylase (TH) expression revealed no TH-immunoreactive (THir) neurons in any animals with hNT neuronal grafts. THir cells were observed in 43% of animals with hNT-DA neuronal grafts and all animals with LiCl pretreated hNT-DA neuronal grafts (100%). The number of THir neurons in these animals was low and not sufficient to produce significant functional recovery. In summary, this study has demonstrated that hNT neurons survive transplantation and express TH in the striatum and SN. Although hNT neurons are promising as an alternative to fetal tissue and may have potential clinical applications in the future, further improvements in enhancing TH expression are needed.", "language": "eng", "dateOfCompletion": "2000-05-23", "fullTextUrlList": {"fullTextUrl": [{"url": "http://dx.doi.org/10.1006/exnr.1999.7337", "documentStyle": "doi", "availability": "Subscription required", "availabilityCode": "S", "site": "ScienceDirect"}]}, "hasTextMinedTerms": "N", "dateOfRevision": "2006-11-15", "hasBook": "N", "journalInfo": {"printPublicationDate": "2000-04-01", "journal": {"medlineAbbreviation": "Exp Neurol", "isoabbreviation": "Exp. Neurol.", "title": "Experimental neurology", "issn": "0014-4886", "nlmid": "0370712", "essn": "1090-2430"}, "monthOfPublication": 4, "volume": "162", "yearOfPublication": 2000, "journalIssueId": 1012549, "issue": "2", "dateOfPublication": "2000 Apr"}}}}